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binding  ability.  Using  the  same  technique  in  macrophages,  miR‐155  was  shown  to 
modulate IL13R1 and STAT6 activation, and to regulate the expression of IL‐13/STAT6 
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(mainly  lymphocytic)  and  antibodies  against  the  pathogens  encountered.  Thus,  it  is 
pathogen‐specific and in many cases results in the so called “immunological memory”, 
which gives lifelong protection against reinfection with the same pathogen (Kindt et al., 
2007;  Murphy  et  al.,  2008).  Adaptive  immune  responses  depend  on  the  pathogen 
encountered and the microenvironment resulting from the interaction between innate 
cells (first barrier) and the given infectious agent.  
  17All  these  cell  types  and  structures  need  to  be  in  continuous  activation  and 






there  they  will  present  the  antigens  (structures  recognized  and  responded  by  the 
adaptive system) to the effector cells‐ lymphocytes (T and B cells). After encountering an 
antigen,  B  cells  proliferate  and  differentiate  into  plasma  cells,  specialized  in  the 
production of antibodies. T cells that are activated by antigen presenting cells (APCs) 
(DCs, Mφs and B cells) proliferate and differentiate into one of several types of effector T 























activation  that  relates  to  these  two  types  of  responses  (Gordon  and  Taylor,  2005; 























Dendritic  cells  are  antigen‐presenting‐cells  that  arise  from  either  myeloid  or 
lymphoid precursors (Doulatov et al., 2010; Geissmann et al., 2010). They are classified 
into  different  subsets  depending  on  their  original  localization,  falling  into  two  main 
categories: conventional DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs can be divided 
into different subcategories depending on their origin, localization and surface marker 























lymphoid  tissue  together  with  nonlymphoid  tissue  SIRPα
+  CD103




all  share  common  features  such  as  morphology  (with  the  typical  dendrites),  high 
expression  of  MHC  (Major  Histocompatibility  Complex)  I  and  II,  intermediate‐high 




































and  13  (IL‐4,  IL‐5  and  IL‐13,  respectively),  inducing  responses  against  extracellular 
pathogens;  they  are  more  related  to  fibrosis,  angiogenesis  and  humoral  (antibody 
production) responses. Correct sensing of pathogens is therefore key in regulating an 














from  dying  cells  and  mature,  migrating  to  lymphoid  tissues  and  presenting  these 
antigens to self‐reactive T cells, inducing self‐tolerance. It has been suggested that these 
“tolerogenic  DCs”  present  self‐antigens  to  T  cells  but  do  not  express  inflammatory 
mediators, therefore inducing tolerance rather than inflammation.  In the case of CD4 T 
cells this may result in the generation of Tregs whilst in the case of cytotoxic CD8 T cells 
the  absence  of  co‐stimulatory  signals  may  be  the  cause  of  self‐tolerance  induction 
(Buckwalter and Albert, 2009a). 
Therefore,  by  directing  the  immune  system  towards  either  inflammation  or 
tolerance,  dendritic  cells  orchestrate  an  efficient  and  appropriate  immune  response 
leading  to  pathogen  clearance.  Unbalanced  responses  underlie  pathologies  such  as 
allergies,  auto‐immune  disesases  or  exacerbated‐inflammatory  diseases  (e.g.  asthma, 
colitis,  psoriasis).  Thus,  regulation  of  DCs  towards  a  balanced  immune  response 
(Th1,/Th2) is central in the control of the immune system and key in health and disease.  




























immune  defence  (Mosser  and  Edwards,  2008),  it  has  been  shown  that  alternatively 
  26activated  macrophages  are  necessary  in  the  host  defence  against  parasites  and 
helminthes (Anthony et al., 2006; Zhao et al., 2008).  
 
Figure  3  Schematic  representation  of  macrophage  activation.  Macrophages  show  two  main 
activation  types:  Classicaly  Activated  Macrophages  (CAMφs  in  red)  and  Alternatively  Activated 







depending  on  the  requirements  and  microenvironment.  Thus,  they  balance  their 




























  281.2  MicroRNAs 
MicroRNAs (miRNAs) are small non‐coding RNAs of approximately 22nt in length 
that inhibit gene expression by pairing to the 3’ UnTranslated Region (3’UTR) of their 










Silencing  (PTGS)  (Beclin  et  al.,  1998;  Vaucheret  et  al.,  1998)  and  quelling  in  fungi 
(Romano and Macino, 1992).  
The first members of the RNAi family, small interference RNAs (siRNAs), were 
discovered by  Andrew J.  Hamilton  and  David C.  Baulcombe  as  a mechanism  of viral 
defence  in  plants  (Hamilton  and  Baulcombe,  1999);  later  siRNAs  were  subsequently 
shown to be effective in mammalian cells (Elbashir et al., 2001). MicroRNAs were initially 
observed in C.elegans as small regulators of development and they were characterized 
by  complementarity  to  their  regulated  mRNAs  (Lee  et  al.,  1993),  athough  the  term 
“microRNA”  was  first  used  several  years  later  (Lagos‐Quintana  et  al.,  2001;  Lee  and 
Ambros, 2001). 
Both siRNAs and miRNAs are derived from double‐stranded RNAs and are found 











transposons,  viruses  or  transgenes,  while  miRNAs  were  described  as  regulators  of 
endogenous genes. 
‐  siRNAs  act  against  specific  genes  whilst  microRNAs  exert  their  action  in  a 
broader range of target genes (Baek et al., 2008; Selbach et al., 2008).  
It is however clear that the criteria that defines the distinction between siRNAs 
and  miRNAs  is  changing.  MiRNAs  have  been  described  as  part  of  the  host  defence 
against viruses (Pedersen et al., 2007) and the evidence for microRNAs exerting their 
inhibitory  functions  via  mRNA  degradation  in  addition  to  translational  inhibition  are 






microRNAs  have  been  shown  to  enhance  transcription  through  binding  to  5’UTR 





  301.2.1  MicroRNA biogenesis 
MiRNAs arise from genome encoded precursors that fold into imperfect hairpin 



















al.,  2001)  reviewed  in  (Carmell  and  Hannon,  2004)  and  Argonaute  (Ago)  proteins  to 
enable them to function as single stranded RNA molecules when loaded in RNA‐induced 




















described  for  this  miRNA*strand,  which  has  been  shown  to  be  conserved  between 
several  species  (Okamura  et  al.,  2008)  and  led  to  their  inclusion  in  the  microRNA 
prediction databases.  
  331.2.2  Mechanisms of miRNA action 
MiRNAs have been reported to exert their function mainly by blocking translation 
and to a lesser extent by cleaving target mRNAs (Filipowicz et al., 2008). Target mRNA 





mRNAs  upon  3’UTR  pairing.  They  exert  post  transcriptional  inhibitory  action  by  four 
different mechanisms: i) inhibiting translation initiation (Humphreys et al., 2005; Pillai et 















site  in  the  targeted  3´UTR  by  Watson‐Crick  interactions  (GC,  AU‐  G:  guanosine,  C: 
cytosine, A: adenine, U: uracil) and directs the RISC action (Bartel, 2004). Importantly, 
G:U “wobble” interactions are permitted in the pairing. MiRNA:target binding depends 

































complementarity  in  the  seed  region,  conservation  across  species  and  accessibility‐
secondary structure of the targeted UTR (Bartel, 2009). Target site context has also been 

















  371.2.4  MicroRNA 155 
MiR‐155 is  the microRNA encoded in BIC (B‐cell Integration Cluster) gene (or 























issue  showing  that  miR‐155  is  processed  in  Burkitt  lymphomas  (Zhang  et  al.,  2008). 
Recently, the maturation of miR‐155 in murine macrophages has been shown to depend 
  38on the KH‐type splicing regulatory protein (KSRP), an RNA binding protein involved in 
splicing  that  promotes  maturation  of  miR‐155  precursors  when  macrophages  are 
stimulated with LPS (Ruggiero et al., 2009).  




pro  inflammatory  stimuli  (pro‐Th1  or  pro‐M1  macrophages  stimuli): 
polyriboinosinic:polyribocytidylic acid, LPS and  interferons, the latter  requiring TNF‐ 




















  391.3  Hypothesis 

























STS  Pegasus  DRIE  plasma  etcher  (STS,  Sumitomo  Precision  Products  Co.  Ltd., 
Japan) 
Thermo  Scientific  Heraeus  FRESCO  17  Centrifuge  (#CFH‐203‐010K,  Fisher 
Scientific UK Ltd, Leicestershire, UK) 
XCell  SureLock®  Mini‐Cell  and  XCell  II™  Blot  Module  Kit  CE  Mark  (#EI0002, 
Invitrogen Ltd, Paisley, UK) 
 








Anti α ‐ Tubulin  (AA12)  (#sc‐58667,  Santa  Cruz  Biotechnology  Inc.,  Heidelberg, 
Germany) 
Anti beta Actin antibody ‐ Loading Control (ab8227, Abcam plc., Cambridge, UK) 
Anti β ‐ Tubulin  (H‐235)  (#sc‐9104,  Santa  Cruz  Biotechnology  Inc.,  Heidelberg, 
Germany) 





























FITC  using  FluoroTag™  FITC  Conjugation  Kit  (SIGMA‐ALDRICH  COMPANY  LTD., 
Dorset,UK) 






















mini  Quick  Spin  RNA  Columns  (#11814427001,  Roche  Products  Ltd., 
Hertfordshire, UK) 
NaCl  for  molecular  biology  (#71376‐1KG,  SIGMA‐ALDRICH  COMPANY  LTD., 
Dorset, UK) 
N,N,N’,N’‐Tetramethylethylenediamine  (TEMED)  (##161‐0801,  Bio‐Rad, 
California, USA) 

































Sodium  dodecyl  sulphate  (#S/5200/53  C107,  Thermo  Fisher  Scientific  Inc, 
Leicestershire, UK) 






TaqMan®  Universal  PCR  Master  Mix,  No  AmpErase®  UNG  (#4364341,  Applied 
Biosystems, USA, California) 
tert‐Butyl  hydroperoxide  solution  (#19990  SIGMA‐ALDRICH  COMPANY  LTD., 
Dorset, UK) 
TOPO® TA Cloning® Kit (#K450001, Invitrogen Ltd, Paisley, UK) 






































  492.2  Cell culture 
All cell culture was performed under regular culture conditions (37°C and 5%CO2) 
























































  512.3  Cloning 
2.3.1  Vectors generated  
pCDNA3.1.BIC:  This  vector  harbors  the  coding  region  that  contains  microRNA 
155. In order to clone it, the genomic region encompassing miR‐155 in the BIC gene was 
amplified by PCR and cloned using TOPO TA Cloning Kit (Invitrogen) into pCR4 vector, 










in  the  figure)  was  cloned  into  pCR4  TOPO  vector  (first  vector  represented  on  the  left,  pCR4_BIC). 
pCR4_BIC was subsequently digested with Hind III/Xho I enzymes; the excised fragment was cloned into 
pCDNA3.1. empty vector constructing pCDNA3.1.BIC (vector represented on the right). 
  52pSUPER_BIC:  The  same  genomic  fragment  as  above  was  amplified  using  the 






























at  its  3’  end.  After  digestion  with  HindIII+XhoI,  the  excised  fragment  was  subcloned  into  pSUPER 
































  56pRLTK_MUT_3´UTR_PU.1:  this  vector  was  generated  by  site  directed 
mutagenesis on pRLTK_3´UTR_PU1. This vector was mutated in the putative miR‐155 
binding  site  (positions  45  to  51  of  PU.1  3’UTR)  using  the  following  primers: 
3´UTR_MUT_PU.1 FOR  GCC TCC CCG CTG GCC TGA ATT CGA AGC CCT CGC CCG GCC CGG 
3´UTR_MUT_PU.1 REV  CCG GGC CGG GCG AGG GCT TCG AAT TCA GGC CAG CGG GGA 

























pRLTK_WT_IL13RA1_3’UTR:  The  steps  for  constructing  this  vector  are 
summarized in Fig.10. The 3’UTR of IL13RA1 was amplified using 120ng of the plasmid 
clone  HmiT009700‐MT01  (Gene  Copoeia)  as  template  and  the  following  primers: 
IL13RA1_3’UTR_FOR  GGC TGT TAG GGG CAG TGG AG and IL13RA1_3’UTR_REV  CAG 











pCR2.1._3’UTR_IL13RA1  (Fig.10,  left  hand  vector)  and  checked  by  sequencing 
(Geneservice,  Oxford‐Appendix  3).  The  amplified  fragment  was  excised  from 
pCR2.1_2’UTR_IL13RA1 with Bam HI/NotI enzymes and inserted into Not I linearized 
pRLTK (Promega) (Fig.10, right vector). In these cut+filling steps, both insert and vector 
were  then  subjected  to  blunt  ending  with  Klenow  DNA  polymerase.  Vector  was 
dephosphorylated  using  CIP  prior  ligation  of  the  insert.  Both  vector  and  insert  were 
purified using QIAquick PCR Purification Kit (Qiagen) after digestion and filling to ensure 








into  Not  I  digested  and  subsequently  blunt  ended  pRLTK  (Promega)  obtaining 
pRLTK_WT_3’UTR_IL13RA1.  
  59pRLTK__MUT1_3´UTR_IL13RA1  and  pRLTK__MUT2_3´UTR_IL13RA1.  These 
clones were obtained by site directed mutagenesis of pRLTK__WT_3´UTR_IL13RA1 using 








1424  of  IL13RA1  3’UTR;  mutation  of  this  site  led  to  the  construction  of 
pRLTK__MUT2_3´UTR_IL13RA1.  Primers  employed  were  IL13RA1_3’UTR_MUT2_FOR  



























































































































by  Prof.  Angel  L.  Corbi  (Centro  de  Investigaciones  Biologicas,  Madrid,  Spain);  these 
constructs  have  been  previously  described  elsewhere  (Dominguez‐Soto  et  al.,  2005). 
pCD209–468 pXP2 is a reporter vector that harbors a fragment of DC‐SIGN promoter 
containing  a  PU.1  binding  site  at  the  5’  of  a  firefly  luciferase  reporter  gene  (thus, 












cells  were  transfected  with  Superfect  (Qiagen)  following  manufacturer´s  instructions; 
plasmid  DNA  amounts  employed  were:  5μg  of  pLVTHM_BIC  construct  (or 
pLV/tTR_KRAB_Red when appropiate), 3.75μg of pPAX2 and 1.5μg of pMD2G vectors. 
Cell supernatants were collected 48h post transfection and centrifuged at 1500 rpm 






THP‐1  cells  were  doubly  transduced  in  two  different  rounds  of  infection  (of 
double infections as explained in 2.4.1) to generate the THP1‐155 cell line. A first round 
of infection was done with pLENTI_BIC derived‐viruses (two infection steps) to generate 
THP‐1  cells  stably  harbouring  this  construct.  pLENTI_BIC  vector  contained  both  the 
cloned  miR‐155  transgene  (see  2.3.1)  and  a  GFP  marker  under  a  Tet‐On  controlling 
system. Transduced cells were sorted by FACS using GFP as reporter gene. Sorted cells 
were  then  re‐infected  with  pLV‐tTR‐KRAB  containing‐viral  particles  (second  round  of 
infection performed in two infection steps). This viral construct provides inducibility to 

















Response)  elements.  Thus,  in  the  presence  of  tTR‐KRAB  cells  harbouring  pLENTI_BIC 
phages become GFP negative. After the second transduction with pVL‐tTR‐KRAB‐viruses, 
GFP negative cells were sorted. Because this population contained also non‐infected GFP 
negative  cells,  doxycycline  was  added  to  the  medium  to  select  only  miR‐155‐GFP 
containing cells. After culturing cells in the presence of doxycycline during one week, a 
third  sorting  round  was  then  performed  to  purify  only  GFP‐miR‐155  positive  cells, 
population that constituted the THP‐1 155 cell line. 
  642.5  Dual Luciferase system 
The Dual Luciferase Reporter (DLR) system is an in vitro tool to determine the 
translational  effects  of  non‐protein  coding  sequences.  It  consists  on  two  different 
reporter genes, Renilla and Firefly luciferase, in which one is used as reporter and the 














green  and  red  colors.  These  different  light  emissions  are  captured  by  a  luminometer  and  serve  as 
readout of the enzyme quantity in each of the reactions.  






















is  cloned  at  the  5’  end  of  the  reporter  Firefly  luciferase  (Firefly  luc,  in  green).  The  presence  of  a 
transcription factor (TF in red) modulates the transcriptional activity of the Firefly construct, which is 
measured as light emission captured by a luminometer.  




pRLTK,  pRLTK_WT_3´UTR_PU1  or  pRLTK_MUT_3´UTR_PU1  plasmids  were  co‐
transfected with pCDNA3.1.BIC or pCDNA3.1 empty vector into HeLa cells employing 
Superfect (Qiagen) following manufacturer’s instructions. Normalization was done by co‐
transfection  of  pGL3  (Promega).  Assays  were  measured  employing  the  Dual‐Glo  kit 
(Promega).  The  experiments  were  performed  three  times  in  triplicates.  Statistical 
differences were determined using Student’s t test. 
2.6.2  Direct targeting of IL13RA1 by miR‐155 
The  constructs  pRLTK_WT_3´UTR_IL13RA1,  pRLTK_MUT1_3´UTR_IL13RA1  or 
pRLTK_MUT2_3´UTR_IL13RA1  were  co‐transfected  with  pCDNA3.1.BIC  or  pCDNA3.1 
empty  vector  into  HeLa  cells  employing  LT1  (Mirus)  following  manufacturer’s 
instructions.  Normalization  was  achieved  by  co‐transfecting  pGL3  (Promega).  Assays 





Southampton,  UK).  pCD209–468  pXP2  harbours  the  proximal  region  of  DC‐SIGN 
promoter reported to be bound by PU.1 transcription factor (Dominguez‐Soto et al., 
2005).  pCDNA3.1‐PU.1  encodes  for  PU.1  without  3’UTR  (see  2.3.2). 
pCDNA3.1_PU.1_3’UTR construct is explained in 2.3.1. THP‐1 155 cells were transfected 






















  692.7.2  Dendritic Cells transfection 
For the pathogen binding experiments, mature DCs (see 2.2.2) were transfected 


















diffusion.  At  day  3,  some  cells  were  collected  and  checked  for  miR‐155  inhibition. 
10ng/ml  IL‐13  was  added  or  not  to  the  cells  and  these  were  collected  24h  post 
stimulation to check miR‐155 effects on the IL‐13 pathway. 
















  712.9  Reverse Transcription and Real Time PCR analysis 
2.9.1  Reverse Transcription 
2.9.1.1   mRNA reverse transcription 




































Real  Time  PCR  for  microRNAs  was  performed  using  TaqMan®  Universal  PCR 
Master Mix, No AmpErase® UNG following manufacturer’s instructions. miR‐155, RNU6 
and  RNU44  were  detected  using  Applied  Biosystems  TaqMan®  MicroRNA  Assays 
following manufacturer’s instructions.  



























using  Acrylamide/Bis  29:1,  N,N,N’,N’‐Tetramethylethylenediamine  (TEMED)  and 
ammonium persulfate (APS), all from Bio‐Rad. Chapter 4 results were mainly obtained 
using precasted gels from Invitrogen: NuPAGE® Novex 4‐12% Bis‐Tris Gel 1.0 mm, 10 well 






Protein  samples  were  then  transferred  onto  an  Immobilon  polyvinylidene 






















































































then  proliferate  and  develop  the  adaptive  branch  of  the  immune  response  in  a 
pathogen‐specific manner depending also on the microenvironment (Geijtenbeek and 
Gringhuis,  2009;  Murphy  et  al.,  2008).  These  adaptive  immune  responses  can  be 
classified into two main types, Th1 or Th2 (described in 1.1.1 and represented in Fig.1). 





stimuli  like  LPS  (Geijtenbeek  et  al.,  2000c;  Steinman,  2001).  Also  known  as  CD209 
(Cluster  of  Differentiation  209),  DC‐SIGN  binds  to  a  wide  range  of  pathogens  via 
mannose and fucose interactions. Mannose interactions include the ones with Candida 
albicans and the HIV glycoprotein gp120 (Cambi et al., 2003; Curtis et al., 1992). Besides, 
DC‐SIGN  also  promotes  transient  adhesion  with  T  cells  trough  ICAM‐3  recognition, 








MafB  levels  in  order  to  determine  a  dendritic  phenotype  versus  a  macrophagic  one 
(Bakri et al., 2005; Bharadwaj and Agrawal, 2007; Friedman, 2007). The low levels of 
PU.1 in PU.1 (‐/‐) cells achieved by the fusion of PU.1 to the estrogen receptor (PUER) 







(Brunner et  al.,  2007;  Chang  et  al.,  2005a),  being  a  key  transcriptional  factor  in  the 
establishment of a Th2 phenotype.  
Previous  results  in  the  lab  (personal  communication  of  Dr.T.Sanchez‐Elsner) 
suggested  a  possible  implication  of  BIC  (MIR155  HG)  in  inflammatory  (pro‐Th1) 
conditions in human macrophages, and shortly after miR‐155 was shown to be involved 
in  the  inflammatory  response  of  murine  macrophages  (O'Connell  et  al.,  2007). 
Intriguingly, these stimuli can trigger DC maturation and bioinformatics’ in silico tools 
predicted PU.1 as a putative target of miR‐155.  















Maturation  involves  a  series  of  changes  in  DCs  surface  (Fig.2);  typical  features  of 
maturation  are  the  down  regulation  of  DC‐SIGN  and  up  regulation  of  co‐stimulatory 
molecules  like  CD83  or  CD86  required  for  T‐cell  activation  (Steinman,  2001).  These 
phenotypical changes are in accordance with the different roles of DCs before and after 
maturation:  from  sensors  and  pathogen  recognizers  (immature  DCs  or  iDCs)  they 
become antigen presenting cells (mature DCs or mDCs).  
Maturation  can  be  mimicked  in  vitro  by  stimulating  DCs  with  bacterial 
lipopolysacharide (LPS). iDCs (see section 2.2.2) were stimulated or not with 1g/mL LPS 





of  the  population).  These  flow  cytometry  profiles  are  the  validation  proof  for  the 
dendritic cell model and hypothesis, and starting point of work. It is shown one donor 




















respectively)  during  the  course  of  48h.  Levels  of  miR‐155  were  detected  by  specific 
  85reverse  transcription  with  stem  loop  primers  followed  by  Real  Time  PCR  (qPCR) 
amplification and quantification as described in section 2.9.1.2., 2.9.2.2. and 2.9.2.3. Ct 
(Cycle threshold) values of the qPCR for miR‐155 oscillated between 27.5 (iDCs) and 20.5 





































‐  Objective  3:  Co  transfections  of  pRLTK‐based  reporter  constructs  with  or 
without a miR‐155 over expressing vector. Luminometry assays.  
3.4.1  Bioinformatics’ analysis of PU.1 3’UTR::miR‐155 interaction 

















































miR‐155  predicted  site  in  the  3’UTR  of  PU.1  is  conserved  amongst  at  least  7 
species. During the course of this work miR‐155 was shown to target PU.1 3’UTR in mice 
(Vigorito  et  al.,  2007).  microRNA::target  interaction  depends  also  on  RNA  secondary 
structure and site accessibility of the binding site. To test structural diferences in miR‐
155::PU.1  interaction  between  human  and  mouse,  in  silico  structure  analysis  was 
performed. RNA folding of miR‐155::3’UTR interaction was done using RNAHybrid (found 












  933.4.2  Amplification of the 3’UTR of PU.1: cloning of pRLTK_3’UTR_PU.1 
Dual luciferase assay (section 2.5) was performed to test the predicted direct 
































  953.4.3  MiR‐155 directly binds to the 3’UTR of PU.1 
After cloning the 3’UTR of PU.1 and obtaining the wild type and mutant reporter 





Each  reporter  vector  was  co  transfected  with  pCNA3.1_BIC  (over  expressing 
vector for miR‐155) or with empty pCDNA3.1 as control into HeLa cells.  
pRLTK empty vector (pRLTK in Fig.22B) was unaffected by the over expression of 















Luciferase  assay  for  miR‐155  action  on  the  3’UTR  of  PU.1.  pRLTK:  pRLTK  empty  vector;  WT:  pRLTK 
including the wild type 3’UTR of PU.1; MUT: pRLTK including the mutant version for miR‐155 binding site 
on the 3’UTR of PU.1 as shown in A.  
  973.5  Generation of THP‐1 155 cell line 
MiR‐155 was shown to be up regulated by LPS in DCs (Fig.15) which has also been 
reported to induce miR‐155 expression in murine macrophages (O'Connell et al., 2007) 
and  involved  in  the  inflammtory  response  of  human  macrophages  (personal 
communication of Dr.T.Sanchez‐Elsner). LPS is a pro‐inflammatory stimulus that triggers 
different  pathways  such  as  TLR4  and  NFB  which  in  turn  involve  many  other 
downstream targets. Thus, LPS exerts its effects on many targets at the same time (e.g. 
PU.1  and  miR‐155)  that  might  or  might  not  be  directly interrelated.  A  cell line  with 
controllable and titrable miR‐155 expression was developed to analyze the effects of 
miR‐155 over expression on its own and isolate it from other inflammatory pathways 
and  events.  The  chosen  cell  model  was  THP‐1  cell  line  due  to  several  of  its 
characteristics: i) it is of myelocytic origin as DCs and Mφs are; ii) it is known to share 
characteristics  with  human  DCs  (Berges  et  al.,  2005);  iii)  it  is  commonly  used  for 
obtaining  Mφ‐like  cells  (Auwerx,  1991;  Park  et  al.,  2007)  and,  importantly,  iv)  they 
express PU.1.  





















because  its  binding  to  DNA  is  regulated  by  tetracycline  or  a  derivative  such  as 
doxycycline (Doxy). When tetracycline (or Doxy) are added to the medium tTR‐KRAB is 
then sequestered freeing the promoter and allowing gene expression to occur (Deuschle 








binding  to  the  tTR  module,  releasing  promoters  of  both  miR‐155  and  GFP  which  become 
transcriptionally active.  
  1003.5.1  Validation of THP‐1 155 cells 
3.5.1.1 Flow cytometry analysis of THP1‐155 cells 
To validate the inducibility of the system, Doxycycline was added to the medium 
at  different  concentrations  (0.25,  2.5  and  10  g/mL)  and  GFP  was  monitored.  The 


























  1023.6  Determination of miR‐155 effects on PU.1 and DC‐SIGN in 
THP‐1 155 cells 
PU.1 was demonstrated to be directly bound by miR‐155 (Fig. 22B) and it is a 

































see  2.8,  2.9.1.1,  2.9.2.1.  and  2.9.2.3),  respectively.  Both  DC‐SIGN  protein  and  mRNA 
levels were down regulated in the presence higher levels of miR‐155 (Figs.27A and B, 
upper panels +Doxy, respectively). PU.1 protein levels were down regulated when miR‐
155  levels  were  increased  (+Doxy,  middle  panel  in  Fig.27A)  while  PU.1  mRNA  levels 
















and  analyzed  by  flow  cytometry.  %  indicates  percentage  of  positive  cells:  MFI:  Mean  Fluorescence 
Intensity. Stained population was determined by comparison to unstained cells.  
The results shown in Figs.26, 27 and 28 suggested that miR‐155 regulates PU.1 
expression  post  transcriptionally  whilst  it  modulates  transcriptional  DC‐SIGN  activity, 
suggesting this regulation to be mediated via direct targeting of PU.1.  
  1063.6.3  Specifity of miR‐155 effects 
In  order  to  confirm  the  specificity  of  miR‐155  effects  on  PU.1  and  DC‐SIGN 
expression  a  “reverse”  approach  was  assayed  by  blocking  miR‐155.  Anti‐miR‐155 
inhibitor oligonucleotires (Ambion) were transfected into doxycycline treated THP1‐155 
cells  (cells  over  expressing  miR‐155)  (see  2.7.1).  Transfection  efficiency  was  firstly 
checked by flow cytometry using a Cy3 labelled Pre‐miRNA probe (Fig.29A). Almost 90% 
of the population was transfected as shown by the percentage of positively labelled cells 


































pCD209–468  pXP2.  The  bar  graph  in  Figure  30  represents  the  results  of  these 
























reported  less  luciferase  activity.  “+PU.1  No  3’UTR”  shows  that  the  co‐transfection  of  the  DC‐SIGN 







  1103.7  Role of miR‐155 in dendritic cells pathogen binding ability  
Previous  results  have  shown  that  miR‐155  augments  during  dendritic  cell 
maturation  (Fig.15)  while  DC‐SIGN  and  PU.1  are  down  regulated  (Figs.14  and  16, 
respectively); that PU.1 is a direct target of microRNA 155 (Fig.22B) and that miR‐155 
modulates DC‐SIGN expression through PU.1 regulation (Figs.26 and 30). 









  1113.7.1  Anti‐microRNA transfection of dendritic cells 



















(Control  in  Fig.31B).  LPS  up  regulation  was  reduced  when  transfecting  the  highest 
concentration of anti‐microRNA control (500nM Control) when compared to the lowest 
one  (50nM  Control).  It  is  possible  that  the  highest  ammount  of  oligonucleotides 
impaired the maturation of DCs, as the levels of miR‐155 were similar when comparing 
transfections of 500nM of Control and 50nM of Anti‐miR‐155 oligonucleotides. 50nM 













2.11.1)  and  binding  experiments  to  FITC‐gp120  protein  and  C.albicans  conidia  were 
performed 48h post transfection (see 2.11.2 for a detailed protocol). Fig. 32 shows the 
flow  cytometry  profiles  (first  and  second  columns)  and  overlays  (third  column)  of 
transfected  cells  with  Anti‐miR‐Control  (in  blue)  or  Anti‐miR‐155  (in  red) 
oligonucleotides.  As  expected,  Anti‐miR‐155  transfected  DCs  showed  higher  DC‐SIGN 
membrane  expression  compared  to  Control  transfected  cells  (Fig.32,  first  row). 













  1153.8  Discussion 
In search of genes involved in inflammation, BIC (MIR155 HG) was found as a 
candidate up regulated by pro‐Th1 conditions in human macrophages; moreover, miR‐





hematopoiesis  (Laslo  et  al.,  2006;  Scott  et  al.,  1994)  that  has  been  linked  to  Th2 
responses (Brunner et al., 2007; Chang et al., 2005b). PU.1 is also a known transcriptional 
regulator  of  the  pathogen  binding  receptor  DC‐SIGN  (Dominguez‐Soto  et  al.,  2005), 
which is present in dendritic cells and it is regulated during DC maturation induced by 
inflammatory  stimuli.  Linking  miR‐155  and  DC‐SIGN  regulation  through  PU.1targeting 
would prove a new role for this microRNA in DCs pathogen binding abilities. Moreover, it 
would establish a new role for miR‐155 in the initial steps of the immune response. 


















expression  levels.  Both  PU.1  and  DC‐SIGN  protein  levels  were  shown  to  be  down 
regulated and only DC‐SIGN mRNA levels were diminished whilst PU.1 ones remained 
stable (Figs. 26 and 27). These results suggested a post‐transcriptional mechanism for 










miR‐155/PU.1  levels  might  lead  to  aberrant  cell  proliferation  with  leukemogenic 
implications.  




were  therefore  performed  to  test  the  hypothesis  that  miR‐155  modulates  DC‐SIGN 
transcriptional activity through regulation of PU.1 levels. Fig.30 shows that miR‐155 over 













miR‐155  in  immunity.  Pathogen  recognition  is  one  of  the  first  steps  in  the  immune 
response, in which a correct sensing and binding of pathogens is essential to exert a 
balanced  and  effective  response.  It  results  in  the  development  of  different  T  cell 

























  119  1204  Chapter 4. Results: MiR‐155 modulates the IL‐13 


























  121the  IL4Rchain,  providing  docking  sites  for  STAT6.  When  STAT6  is  bound  to  the 
receptor,  it  is  also  phosphorylated  by  JAKs,  becoming  active,  dimerizing  and 
translocating to the the nucleus, where it acts as a transcription factor (Hebenstreit et 
al., 2006). 











main  Th2  cytokines  that  trigger  alternative  (M2)  Mφ  activation  through  the  STAT6 
(Signalling  Transducer  and  Activator  of  Transcription  6)  signalling  cascade,  a  typical 
Th2/M2  signalling  pathway  (Hebenstreit  et  al.,  2006;  Hershey,  2003;  Martinez  et  al., 
2009; Wynn, 2003). 
  1224.2  Hypothesis and aims 
4.2.1  Hypothesis 









To  avoid  confussion,  the  term  “IL13RA1”  will  be  used  when  referring  to  the 
gene/mRNA and “IL13R1” to the protein henceforth. 






























  1254.3.1.1  microRNA.org 
microRNA.org is a microRNA::target prediction tool and database available on 
line  at  (http://www.microrna.org/microrna/home.do).  It  employs  miRanda  algorithm, 
which uses a method based on the conservation of evolutionary relationships between 




included  in  the  Vienna  package,  a  compilation  of  RNA  folding  algorithms  and  tools 
(Hofacker et al., 1994; McCaskill, 1990; Zuker and Stiegler, 1981).  
microRNA.org  was  released  in  January  2008;  in  this  version  miR‐155  was 
predicted to target the 3’UTR of IL13RA1 in two different sites shown in Figure 33 that 
map to nucleotides 1049‐1071 (named as Site 1) and 1399‐1424 (named Site 2) of the 




























Figure  34  Predicted  structures  for  miR‐155::IL13RA1  3’UTR  binding  sites.  Red  indicates  the 
3’UTR  sequence  that  is  predicted  to  interact  with  miR‐155  (in  green).  Energies  indicated  are  the 
predicted energy values released in each one of sites. Site 1 maps to nucleotides 1049‐1071 and Site 2 to 
1399‐1424  in  the  3’UTR  of  IL13RA1.  Downloaded  from  RNAHybrid  (http://bibiserv.techfak.uni‐
bielefeld.de/rnahybrid/submission.html) 





mutagenesis  was  performed  in  each  one  of  the  predicted  binding  sites: 






































were  performed  in  triplicates  and  it  is  shown  one  of  them.  Statistical  analysis  was 
performed using t‐test with GraphPad Prism version 5.00 for Windows.  
These data indicarte that miR‐155 directly binds to the 3’UTR of IL13RA1 and that 





version  of  Site  2  (nucleotides  1399‐1424)  of  the  3’UTR  of  IL13RA1.  B:  Reporter  constructs  were  co 
transfected  with  empty  pCDNA3.1  (white  bars, ‐ )  or  pCDNA3.1_BIC  (black  bars,  miR‐155).  When 
mutating any of the predicted sites (MUT1 and MUT2) the over expression of miR‐155 (black bars) 
showed no effect. It is shown one experiment of three replicates. *: P‐value≤0.05 








pathways  activated  by  pro‐inflammatory  stimuli  that  trigger  miR‐155  up  regulation 
(O'Connell et al., 2007) and Fig.15. Moreover, THP‐1 cells are commonly used to study 
macrophage  biology  (Auwerx,  1991;  Park  et  al.,  2007)  and  therefore  provide  a 
macrophage‐like environment to study miR‐155 effects.  
The  aim  was  to  determine  miR‐155  over  expression  effects  on  endogenous 
IL13RA1 expression. IL13RA1 is part of the Type II IL‐4 receptors and triggers STAT6 














experiment  that  was  performed  three  times.  ‐tubulin  was  used  as  loading  control. 
Figure 38A shows that upon addition of doxycycline, IL13R1 protein levels dropped to 
4% of its original value (start of the treatment). Fig.38B shows the results of the RT‐qPCR 





























control.  Importantly,  cells  unstimulated  showed  no  basal  activation  regardless  of 









Once  observed  miR‐155  effects  on  both  IL‐4  and  IL‐13  dependent 
phosphorylation of STAT6, and since IL‐13‐dependent phosphorylation of STAT6 solely 







THP1‐155  cells  were  treated  as  before  (section  4.4.2.1)  and  total  STAT6  protein 
expression measured by western blot (see 2.10). Fig. 40 shows that STAT6 protein levels 
are not altered by miR‐155 over expression (+ Doxy) or IL‐13 stimulation. Thus, the lower 
P‐STAT6  levels  when  miR‐155  is  up  regulated  (Fig.  39)  do  not  depend  on  the  total 


















at  1h  and  reached  50%  of  the  P‐STAT6  levels  when  compared  with  no  doxycycline 
treated cells (‐Doxy, in blue). These experiments showed that miR‐155 over expression 
















THP1‐155  cells  are  an  excellent  system  to  test  myeloid  target  genes  but  it  has  the 
limitations of a cell line. In order to more closely match physiological conditions, Mφs 
were analyzed employing Anti‐miR‐155 transfections. The objectives established were:  












monocytes  were  incubated  in  the  presence  of  50nM  Cy3‐labelled  Control  microRNA 
(Ambion) oligonucleotides and transfection efficency was checked by flow cytometry 3 
days later. Section 2.7.3 details the transfection conditions. Before checking the cells in 

















(Anti‐miRNA  Control  hence  foth)  (both  from  Ambion)  were  employed.  Cells  were 
collected at day 5 and miR‐155 expression analyzed by RT‐qPCR (see 2.8, 2.9.1.2, 2.9.2.2 
and  2.9.2.3)  normalising  with  RNU44.  Values  shown  in  Fig.43  are  the  relative  fold 
induction of miR‐155 compared to day 0.  
Both  doses  showed  miR‐155  knock  down  (Fig.43,  black  bars  in  both  graphs). 
However, the double dose (“Extra dose”in Fig.43) showed to alter cells response to IL‐
13: this cytokine led to up regulation of miR‐155 in the control transfection more than 30 
times  when  compared  to  the  single  dose  (“Normal  dose”in  Fig.43).  Monocyte  to 
macrophage differentiation up regulates miR‐155 expression (personal communication 
of Dr. T. Sanchez‐Elsner); however, this up regulation was around 3 times lower when 
Anti‐miR‐155  oligonucleotides  were  retransfected  twice.  This  proved  some  instability 
under these conditions and it was therefore decided to use the single (“Normal dose” in 

















and  cells  were  collected  2h  post  stimulation  to  check  IL13R1  and  phospho‐STAT6 
proteins by western blotting. In both experiments ‐tubulin was used as loading control. 
Figure 44A shows the results for IL13R1 protein expression by western blot 

































genes  of  the  IL‐13/STAT6  signalling  cascade  in  primary  Mφs  based  on  previous 
observations (Hebenstreit et al., 2006; Mantovani et al., 2004; Martinez et al., 2006; 













































































































































































































cells  (Fig.46,  IL‐13).  Anti‐miR‐155  transfection  showed  no  significant  effect  in 
unstimulated  cells  (Fig.46,  Unstimulated).  These  results  followed  the  previous 
observations:  blocking  miR‐155  up  regulated  IL13R1  protein  expression  and 













  1514.7  Discussion 










reprogramming  and  activation  and  miR‐155  was  involved  in  M1  profiling.  It  was 
hypothesised that if miR‐155 targetted pro‐M2 factors the Mφ profile would be skewed 
towards a M1 phenotype. Using in silico tools in search of pro‐M2 factors, IL13RA1 was 






IL13RA1  cannot  be  excluded,  although  no  favourable  predictions  were  identified 
(discussed in section 4.3.1.2).  
Using  THP1‐155  cells,  which  provide  a  myeloid  environment  and  model  a 
macrophage‐like cell system (Auwerx, 1991; Park et al., 2007), it was shown that miR‐


























mRNA  remained  stable  (Fig.44A  and  44B,  respectively).  This  suggested  a  post 











al.,  2009)  and  miR‐155  direct  action  on  this  gene  cannot  therefore  be  excluded  in 
macrophages. However, SOCS1 mRNA expression did not show significant up regulation 










II  IL‐4  receptors,  the  development  of  a  knock  out  model  for  IL13RA1  allowed 








(Wills‐Karp,  2004).  One  of  the  genes  induced  by  IL‐13  is  CD23,  the  low‐affinity 
immunoglobulin (Ig) E receptor (FcepsilonRII). CD23 in triggered by CD23 in Mφs and 
binds to IgE complexes promoting an inflammatory response and has been shown to 
play  an  important  role  in  allergy,  asthma  and  antigen  presentation  amongst  other 
functions (Rambert et al., 2009; Rosenwasser and Meng, 2005). Moreover, it is one of 







leveles  of  miR‐155  contribute  to  the  exacerbated  immune  response  observed  in 
asthmatic  patients  by  skewing  and  unbalancing  the  Th1/Th2  reponses:  less  targeting 
IL13R1  would  enhance  IL‐13  signalling,  modulating  CD23,  CCL18,  SOCS1  and  other 
targets which in combination would promote a pro‐Th2 environment in the lung, as the 
one  observed  in  asthma  disease  and  related  to  IL‐13  expression  (Wills‐Karp,  2004). 
Moreover, anti‐STAT6 siRNA inhalation has been shown to diminish airway inflammation 
and hyperreactivity in lungs (Darcan‐Nicolaisen et al., 2009). These data and assays open 




regulating  their  fibrotic/remodeling  capabilities.  M2  macrophages  show  a  more 






Together,  all  these  data  indicate  that  miR‐155  is  positioned  at  the  core  of 
immune regulation. By direct targeting of IL13R1, miR‐155 modulates IL‐13 pathway in 
macrophages,  a  typical cytokine  that  triggers alternative activation  of  Mφs.  MiR‐155 
seems to play a center role in the plasticity displayed by macrophages, constituing an 
excellent  example  of  microRNA  function:  a  fine  regulator  in  a  system  that  requires 
constant balance and plasticity, key facts of microRNA biology. 










































single  cell  events,  control  changes  in  the  microenvironment  and  perform  real  time 










is  the  work  by  (Mempel  et  al.,  2004)  which  measured cell  to  cell  contacts  between 
murine  DCs  and  lymphocytes  in  vivo  using  microscopy.  Nevertheless,  there  are  still 
questions and processes which study is limited by current lab techniques and animal 
models.  Examples  are  measuring  minimal  cell  distances  required  for  cell  to  cell 
communication, determining requirements for cell to cell contact and especially real 
  158time  monitoring  of  single  cell  changes.  These  are  essential  processes  that  allow  the 
orchestration of several cell types and responses (like DCs and Mφs do) which will result 
















  1595.2  Aims and objectives 













  1605.3  Design of the masks 
Two different designs were required for the device: one design for “cell traps” 






































spacing  between  columns  was  20  m,  corresponding  to  1‐1.5  mm  cell  diameters 
approximately as previously suggested (Skelley et al., 2009). 
The  dimensions  of  the  hollows  in  the  H  traps  were  designed  to  be  18  m: 
theoretically big enough to fit a single cell and small enough not to trap two cells. This 
hollow size was decided by comparison of THP‐1 cells distortion studies and HeLa cell 
dimensions  (Kurosaka  et  al.,  1998;  Skelley  et  al.,  2009)  to  DCs  and  Mφs  under  the 




















to  minimize  the  risk  of  piercing  the  whole  device  when  trying  to  flow  in  the  cells. 
Modelling of the flow dynamics was done by Dr. S. Birtwell using the dimensions of a 






























Figure  52  Overview  of  the  photolitography  procedure.  Masks  designed  with  CleWin  were 
patterned with chrome by a mask manufacturer onto glass masks. A silicon disk was used as substrate 
on which a negative photoresist was spun to a desired thickness. Masks patterns were then transferred 




















After  this  step  the  photoresist  was  developed  using  AZ
®  400K  Developer  in  a 
dilution 1:3 in water during 90 secs. This step removed the photoresist not exposed to 
light, this is, the chromed patterns in the glass mask. The definition of the patterned 















performed:  coating  with  C4F8  in  the  STS  Pegasus  DRIE.  This  layer  prevents  PDMS 





Figure  53  Section  of  the  device  showing  the  etched  silicon  wafer.  Rows  of  traps  were  not 
parallels  (see  Fig.  50B)  and  this  is  indicated  by  the  dotted  lines.  This  patterned  mold  was  used 
afterwards for PDMS molding and device making. 
  1695.5  Soft lithography: making devices in PDMS 
For the following steps (soft lithography and device tests), Dr. Marta Lombardini 
helped  and  fully  collaborated  especially  regarding  the  flow  workout  and  loading 
conditions.  
Soft  lithography  consisted  on  the  patterning  of  elastomeric  stamps  in  PDMS 




plasma  treatment;  its  elasticity  allows  building  of  valves,  pumps  and  pipes  that  are 




























  1725.6  Flow workout using THP‐1 cells 
5.6.1  Loading overview 
THP‐1 cells were initially used to test the device as these are easily cultured and 



















































































were  incubated  with  tert‐butyl  hydroperoxide  (TBHP)  which  induces  oxidative  stress 
(Garcia‐Cohen et al., 2000), conditions that induce H2DCFDA to fluoresce. TBHP was used 
instead of H2O2 (commonly used for ROS assays) as it is more stable and biocompatible.  
This  experiment  was  also  a  measure  of  the  biocompatibility  of  the  system 
(device,  pumps,  pipes,  etc):  cells  under  stress  would  produce  ROS  and  appear 
fluorescent  under  the  microscope.  This  was  useful  as  cellular  stress  modify  cell 


















cell  behaviour  inside  the  designed  device.  DCs  had  already  been  shown  to  bind  to 
pathogens (see 3.7.2) and performing binding assay inside the device would give insight 

























microscope  within  an  environmentally  controlled  chamber  (37°C  and  5%CO2)  which 















producing  DC  captured  C.albicans  conidia.  This  event  took  20  min  approximately  to 
occur. Interestingly, DCs were able to sense and phagocytose dead C.albicans, as conidia 
were heat inactivated and then stained with propidium iodide (see 2.11.2.1). Propidium 






phagocytosis events  taken at  time  intervals  of 10, 15 and  20  min  (below pictures)  by fluorescence 
microscopy  are  shown.  A:  A  propidium  iodide  labelled  C.albicans  conidium  (indicated  with  a  white 
arrow) moves from one side of the trap to the other side which harboured a DC. B: A ROS producing DC 
(in green) phagocytosed C.albicans conidia labelled with propidium iodide (in red) is shown.  
  1825.8  Discussion 
Cell to cell communication has proved difficult to investigate and observe in a one 
to one basis. Developing a single cell trapping system to monitor events in single cells 










based  on  previous  studies  (Skelley  et  al.,  2009)  and  considering  the  mechanically‐













possibilities  that  makes  this  type  of  microdevices  a  superb  tool  for  biological  work. 
Importantly, PDMS is a low cost material that is commercially available which makes it of 
value for developing disposable devices. 




probe  that  fluoresces  upon  oxidation  (see  2.11.3)  and  they  showed  no  fluorescence 
when compared to cells engaged in ROS production (Fig.60). 





instantly  produced  measured  as  fluorescence  that  decreased  afterwards,  taking 
approximately  20min  to  fade  away.  However,  it  was  only  possible  to  perform  this 
experiment once (data not shown) and needs further testing (see 6.2.2). 





device  to  measure  the  effect  of  miR‐155  over‐expression  on  the  ability  of  cells  to  
interact  with  C.albicans  conidia  at  the  single  cell  level.  This  approach  could  reveal 
































an  effective  response,  the  immune  system  regulates  and  coordinates  its  two  main 
branches,  innate  and  adaptive  immunity:  “general  troops”  (innate  response)  and 
“specialized killers” (adaptive response) in analogy with a war against a given pathogen.  
















In  search  of  genes  differentially  expressed  under  pro‐  or  anti‐inflammatory 
conditions, BIC (MIR155 HG) had been found to be involved in the inflammatory profile 
of  human  macrophages;  coincidentally,  microRNA‐155  was  found  up  regulated  by 
inflammatory conditions in murine Mφs (O'Connell et al., 2007). MicroRNAs are small 
non‐coding RNAs of ~22nt in length that inhibit gene expression upon pairing to the 
  1873’UTR  of  their  target  genes  mRNA  (Bartel,  2004).  MiRNAs  can  exert  their  inhibitory 
functions  on  a  wide  range  of  target  genes  upon  binding  to  sites  in  their  3’UTRs 
(summarized in Fig.5), putatively regulating hundreds of targets (Bartel, 2009).  
Thus, microRNAs are ideal candidates in the context of Th1/Th2 responses, in 
which  they  may  potentially  act  as  regulators  between  these  two  profiles.  It  was 
therefore proposed that miR‐155 is involved in the pro‐Th1 response of macrophages by 
down regulating pro‐Th2 factors.  







































miR‐155  to  down  regulate  IL13RA1  expression.  This  could  be  a  case  of  microRNA 
cooperativity (Vella et al., 2004) in which miR‐155 binding to one site facilitates access to 




















PU.1  and  DC‐SIGN  levels  were  determined.  MiR‐155  over  expression  led  to  a  down 
regulation of both PU.1 and DC‐SIGN at the protein level; PU.1 mRNA levels remained 
stable  while  DC‐SIGN  mRNA  expression  was  down  regulated  (Figs.  26,  27  and  28). 
Similarly, IL13RA1 protein levels showed down regulation upon miR‐155 over expression 





levels  down  regulation  (Guo  et  al.,  2010).  Nevertheless,  microRNAs  can  exert  their 
inhibitory  functions  in  two  ways:  inhibiting  the  mRNA  translation  or  promoting  the 












mRNA  levels  (Fig.16);  together  with  the  results  obtained  in  THP1‐155  cells  (Fig.26) 
suggests  several  possibilities:  i)  miR‐155  regulates  PU.1  by  different  mechanisms 
depending on the cell environment (in a dose/time dependent manner, promoting PU.1 
degradation in DCs and PU.1 mRNA translation blockage in THP1‐155 cells); ii) miR‐155 
regulates  PU.1  in  DCs  but  PU.1  is  also  regulated  at  a  pre  transcriptional  level;  iii)  a 
combination of both. Further studies might address these possibilities (see 6.2.1). 
Alternatively,  levels  of  both  protein  and  mRNA  of  DC‐SIGN  showed  down 
regulation upon miR‐155 over expression in THP1‐155 cells (Figs. 27 and 28) suggesting a 
pre  transcriptional  role  for  miR‐155  in  the  regulation  of  DC‐SIGN.  PU.1  is  a  known 
transcriptional regulator of DC‐SIGN in myeloid cells (Dominguez‐Soto et al., 2005) and it 










IL‐4  can  bind  also  to  IL‐4  Type  I  receptors  (Junttila  et  al.,  2008)  but  IL‐13  triggering 
phosphorylation of STAT6 depends solely on the presence of IL13R1 (Hershey, 2003). 
THP1‐155  cells  over  expressing  miR‐155  showed  diminished  STAT6  phosphorylation 






IL13RA1.  As  IL‐4  can  also  signal  through  Type  I  receptors  leading  to  STAT6 






















(Fig.38).  Consequently,  Anti‐miR‐155  transfected  Mφs  showed  enhanced  IL‐13 


















device  was  designed  (see  5.3).  This  type  of  Lab  on  a  Chip  devices  allow  single  cell 












currently  under  development.  Interestingly,  out  of  the  three  distances  assayed  (see 













and  it  is  induced  by  Th2  stimuli  (Puig‐Kroger  et  al.,  2004;  Relloso  et  al.,  2002). 
Interestingly,  mice  lacking  IL13RA1  show  lack  of  hyper  reactivity  and  mucus 
hypersecretion in the lungs (Ramalingam et al., 2008) and the same murine model has 
shown the  role of IL13RA1 in allergen induced lung pathology (Munitz et al., 2008). 
Moreover,  mice  treated  with  siRNA  against  STAT6  show  diminished  airway  hyper 
reactivity and inflammation in a model of Th2 lung response (Darcan‐Nicolaisen et al., 












2007).  Interestingly,  Th2  cytokines  induce  DC‐SIGN  expression  in  myeloid  cells  (Puig‐
Kroger et al., 2004; Relloso et al., 2002) placing DC‐SIGN in a pro‐Th2 immune context, 










pro‐pathological  environment  may  contribute  to  the  development  of  these 
“multifactorial” diseases, in which several genes are candidates that contribute to the 
development of a given phenotype. As an example, CCL18, IL‐13, STAT6 or SOCS1 (direct 
or  indirect  targets  of  miR‐155,  see  Figs.44  and  46)  have  been  involved  in  asthma 
pathogenesis (Borowski et al., 2008; Darcan‐Nicolaisen et al., 2009; de Nadai et al., 2006; 




















Investigating  longer  times  of  miR‐155  over  expression  in  THP1‐155  cells  might  show 




different  proteins.  qPCR  analysis  would  reveal  mRNA  regulation  and  this  is  also  a 
possibility  to  explore  employing  longer  miR‐155  over  expression  times  than  those 
employed (96h, Figs. 24 and 25). In addition, polyribosome profiling would reveal the 




employing  PU.1  promoter  assays  dependent  on  miR‐155  levels  similar  to  those 
presented  for  DC‐SIGN  regulation  (Fig.  30)  could  reveal  and  give  insight  to  this 
hypothesis. 





Little  is  known  about  the  interaction  and  communication  between  antigen 
presenting  cells,  or  regarding  the  intercellular  distances  required.  This  may  be  of 
importance as it has been shown that the time and frequency of contact between cells 
































serve  as  auto‐vaccines.  Combining  microfluidics  and  biology  broadens  our  current 
knowledge and will most likely change the way biology is analyzed towards becoming a 
more precise and, possibly, mathematical science. 














the  resulting  construct  was  named  pCDNA_BIC  and  the  cloned  sequence  is  detailed 
bellow. According to BLAST it maps to locus NT_011512.11 (GRCh37). Blue sequence 
corresponds  to  MIR155  HG;  underlined  nucleotides  shaded  in  grey  correspond  to 
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MicroRNA-155 (miR-155) has been involved in the response
to inflammation in macrophages and lymphocytes. Here we
show how miR-155 participates in the maturation of human
dendritic cells (DC) and modulates pathogen binding by down-
regulating DC-specific intercellular adhesion molecule-3 grab-
bing non-integrin (DC-SIGN), after directly targeting the tran-
scription factor PU.1. During the maturation of DCs, miR-155
increases up to 130-fold, whereas PU.1 protein levels decrease
accordingly. We establish that human PU.1 is a direct target for
miR-155 and localize the target sequence for miR-155 in the
3 -untranslated region of PU.1. Also, overexpression of miR-
155intheTHP1monocyticcelllinedecreasesPU.1proteinlev-
els and DC-SIGN at both the mRNA and protein levels. We
prove a link between the down-regulation of PU.1 and reduced
transcriptional activity of the DC-SIGN promoter, which is
likely to be the basis for its reduced mRNA expression, after
miR-155overexpression.Finally,weshowthat,byreducingDC-




which miR-155 regulates proteins involved in the cellular
immune response against pathogens that could have clinical
implications in the way pathogens enter the human organism.
MicroRNAs have emerged as important regulators of key
cellularprocesses.Theyconsistofendogenoussmall,non-cod-
ing RNA molecules of about 19–22 nucleotides in length (1),
which regulate mRNAs in a post-transcriptional manner. They
bind to the 3-untranslated regions of their target mRNAs and
exert their function in two ways: mainly blocking the transla-
tion and also inducing their cleavage in a similar fashion to
small interfering RNAs (2). MicroRNAs are initially expressed
as long immature pri-microRNAs, which are processed in the
nucleusintotheprecursorpre-microRNAsandfinallymatured
byDicerinthecytoplasmintothefunctional19–22-nucleotide
long microRNAs, which are then incorporated into the RNA-
induced silencing complex (1).
The role of microRNAs is being intensively studied in many
different fields such as fetal development and the immune sys-
tem. One of the miRNAs that appears to play a particularly
important role in the immune system is microRNA-155 (miR-
155),
3 the expression of which is induced by inflammatory sig-
nals such as exposure to antigen, Toll-like receptor ligands, or
interferon  stimulation in T-cells, B-cells, and macrophages,
respectively (3, 4).
miR-155 knock-out mice show aberrant immune functions
including defective B and T cell immunity and abnormal func-
tion of antigen-presenting cells (4, 5). These mutant mice
exhibit an imbalance in the immune Th1/Th2 response, with
the CD4 T cells biased toward Th2 differentiation (4). A lack
of miR-155 also leads to a failure in production of high-affinity
IgG1 antibodies by murine B-cells (28). This effect has been
relatedtoitsabilitytotargetthetranscriptionfactorPU.1,akey
transcription factor in human hematopoiesis, restricted to B
lymphoid, granulocytic, and monocytic cells (6).
So far, the role of miR-155 in dendritic cell biology has not
been studied in depth. Dendritic cells (DCs) are professional
antigen presenting cells that have a pivotal role in controlling
immune responses, directing them toward immune activation
or tolerance (7), orchestrating an efficient and protective
immune response. DCs are present as sentinels in peripheral
tissues where they capture antigens that will be presented to
CD4andCD8Tcellsinlymphoidorgans.Theyariseeither
from myeloid- or lymphoid-derived precursors and exhibit an
immaturephenotypecharacterizedbyahighphagocyticcapac-
ity and low expression of co-stimulatory molecules (8). DCs
undergoamaturationprocessafter“sensing”pathogen-derived
structures through pattern recognition receptors such as Toll-
likereceptors,exposuretopro-inflammatorycytokines,orafter
ligation of the surface receptor CD40. Upon maturation, DCs
stop taking up antigens and change their pattern of homing
receptors, acquiring a phenotype that allows them to migrate
intotheTcellcompartments,wheretheyperformtheirantigen
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Supplemental Material can be found at:presentingfunction.ManytranscriptionfactorssuchasNF-B
and PU.1 are involved in this process, although no microRNA
has been implicated so far.
InadditiontoitsroleinDCmaturation,PU.1hasbeenimpli-
cated in the differentiation of DCs from myeloid precursors. In
this process, the balance between PU.1 and MafB determines
the phenotype as being a dendritic cell or a macrophage (9).
PU.1 controls a number of myeloid genes, and it has been
shown to contribute to transcriptional expression of DC-SIGN
(CD209) (10). DC-SIGN is a C-type lectin, present in myeloid
dendritic cells, that binds a large array of pathogens via man-
nan- and Lewis oligosaccharides-dependent interactions (11–
15). For example, it has been proposed that DC-SIGN binds to
HIV-1,facilitatingtransportofthevirusbyDCs’migratinginto
thelymphnodes,thuspromotingtransinfectionofCD4lym-
phocytes (16). Moreover, CD209 mediates transient adhesion
contact with T cells through intercellular adhesion molecule 3
recognition, (17), DC transmigration across endothelium via
intercellular adhesion molecule 2 interactions (18), and inter-
action with neutrophils via Mac-1 (19). DC-SIGN is mainly
expressed in DCs and macrophages activated by interleukin-4,
andisdown-regulatedtogetherwithPU.1duringmaturationof
human DCs (10).
In this report, we demonstrate that miR-155 levels increase
during maturation of human monocyte-derived dendritic cells
after exposure to lipopolysaccharide (LPS). We show that
humanmiR-155directlytargetsthe3-untranslatedregion(3-
UTR) of PU.1 mRNA and we map the target sequence for miR-
155binding.Wealsopresentastablytransfected,induciblecell
system using the THP-1 monocytic cell line. This cell line,
hence forth named THP1–155, was able to overexpress miR-
155 in a regulated fashion, after treatment with doxycycline. In
this system, we prove that overexpression of miR-155 elicits
proteinleveldown-regulationofPU.1andsubsequentlyofDC-
SIGN mRNA and protein. Furthermore, we demonstrate that
miR-155reductionincreasedDC-SIGNlevelsinthemembrane
of DCs resulting in impaired pathogen binding capacity. Thus,
inhibition of miR-155 by synthetic oligonucleotides increased
the binding of DCs to both Candida albicans and HIV-1 pro-
tein (gp120). Our results show how DC-SIGN, a protein of
functionalimportanceintheimmunesystem,isregulatedindi-
rectlybymiR-155bydirecttargetingofthetranscriptionfactor
PU.1. This has an important physiological role in the pathogen





mononuclear cells as previously described (20). Monocytes
were cultured for 5–7 days in complete medium (RPMI 1640
medium supplemented with 10% fetal calf serum) with 1000
units/ml granulocyte macrophage-colony stimulating factor
and 1000 units/ml interleukin-4 (Immunotools) to obtain
immatureDCs.TomaturetheseDCs,ultrapureLPSfromEsch-
erichia coli 0111:B4 (1 g/ml) was used. The cell line THP1–
155 was cultured in RPMI complete medium. HEK293T and
HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium plus 10% fetal calf serum.
VectorsGenerated
pCDNA3.1.BIC—The genomic region encompassing
miR-155 was amplified and cloned into HindIII/XhoI of the
pCDNA3.1 multicloning site. Primers employed were BIC-
FOR, AAGCTTTATGCCTCATCCTCTGAGTGC and BIC-
REV, CTCGAGACGAAGGTTGAACATCCCAGTGACC.
pLVTHM_BIC—The same fragment as above was first
cloned in pSUPER in the HindIII/XhoI sites, from where it was
removed using EcoRI and MluI sites, and then subcloned into
pLVTHM.pRLTK_WT_3UTR_PU1wasgeneratedbycloning
the 3-UTR of human PU.1 into XbaI and NotI sites of the
pRLTK vector (Promega). PU.1 3UTR was amplified from
genomic DNA by PCR amplification following the protocol
established by Ralser et al. (21) using the following primers:
3-UTR PU.1 FOR2 (TCT AGA TAC GAC TTC AGC GGC
GAA GTG CTG) and 3-UTR PU.1 REV BamHI (GGA TCC
GGA TTG AGA ATA ACT TTA CTT G). pRLTK_MUT_
3UTR_PU1 was generated by site-directed mutagenesis on
pRLTK_WT_3UTR_PU1. This vector was mutated in the
putative miR-155 binding site, using the following primers:
3UTR_Mut_PU.1FOR(GCCTCCCCGCTGGCCTGAATT
CGAAGCCCTCGCCCGGCCCGG)and3UTR_Mut_PU.1
REV (CCG GGC CGG GCG AGG GCT TCG AAT TCA GGC
CAG CGG GGA GGC). Mutagenesis was done using the
QuikChange  Site-directed Mutagenesis Kit (Stratagene) and
following the manufacturer’s instructions.
Transfections
To generate the THP1–155 cell line, HEK293 T cells were
transfected with Superfect (Qiagen) following the manufactur-
er’s protocol with 5 g of pLVTHM_BIC (or pLV/
tTR_KRAB_Red in the case of generating the repressor lentivi-
ral particles), 3.75 g of pPAX2 and 1.5 g of pMD2G.
Supernatant from these cells, containing lentiviral particles,
was added to THP-1 cells that were preincubated in the pres-
enceof8g/mlofPolybrene(Sigma)for30minat37 °C.Infec-
tion was checked 4 days after infection, and positive cells were
sorted. All the vectors used in the lentiviral system were kindly
provided by Prof. Didier Trono (Ecole Polytechnique Fe ´de ´rale
de Lausanne, Switzerland).
For the luciferase promoter assays, we used the pCD209–
468pXP2reporterplasmid,whichcontainstheproximalregion
of the DC-SIGN promoter and pCDNA3.1-PU.1 encoding for
full-length PU.1 (10). These plasmids were kindly provided by
Prof. A. L. Corbi (Centro de Investigaciones Biologicas, CSIC,
Spain).pCDNA3.1_PU.1_3UTRwasgeneratedbyinsertingthe
3-UTR of PU.1 after the coding region of pCDNA3.1 employ-
ing a blunt end ligation strategy. THP1–155 cells were electro-
poratedfollowingstandardprocedures.Electroporationresults
were normalized by co-transfection with the pRLTK-Renilla
luciferase plasmid. To assess direct targeting of miR-155,
pRLTK, pRLTK_WT_3UTR_PU1, or pRLTK_MUT_3UTR_
PU1 were transfected into HeLa cells employing Superfect
(Qiagen) following the manufacturer’s instructions.
pCDNA3.1.BIC or pCDNA3.1 empty vector was co-trans-
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 fected. Normalization was achieved with co-transfection of
pGL3 (Promega). All luciferase/Renilla luciferase assays were
measured employing the Dual-Glo kit from Promega. The
experimentswereperformedthreetimesintriplicates.Statisti-
cal differences were determined using Student’s t test.
FlowCytometry
For the pathogen binding experiments, mature DCs were
transfected with 100 nM of oligonucleotides anti-miR-155 or
anti-miR-Control, and 50 nM Cy3-premiR-control-1 (Ambion)
at day 5 of culture. Cy3 fluorescence was used both to assess
transfection efficiency and to specifically select the transfected
population of DCs. DC-SIGN surface expression was checked
by flow cytometry, using 0.3 ng/l APC-anti-human DC-SIGN
antibody or APC Rat IgG2a as Isotype Control (eBiosciences).
To perform the binding assays, C. albicans was resuspended in
phosphate-buffered saline, inactivated at 90 °C for 20 min, and
stained using propidium iodide (1 mg/ml) for1ha t4° Cwith
shaking. Blocking of DC-SIGN was done using 20 g/ml of
AZND1 (Beckman Coulter) or a matched isotype, incubating
cellsfor20minatroomtemperature.Cellswerethenfixedwith
CellFix(BDBioscience)for30minat4 °C,andlabeledCandida
conidia or gp120-fluorescein isothiocyanate (Trinity Biotech)
were added. Binding was performed in binding buffer (20 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2,2m M MgCl2, and 1%
bovineserumalbumin),afterwhichcellswerewashedandana-
lyzed by flow cytometry (FACSAria, BD Biosciences). Data
were processed with the program FlowJo.
RTandqPCRAnalysis
RNA samples were obtained using the TRIzol isolation
(Invitrogen) method. Real time PCR using Applied Biosystems
TaqMan  MicroRNA Assays was used to detect both mature
miR-155andthehousekeepingRNU6B,whichwasusedasnor-
malizing control. These assays were performed following the
manufacturer’s instructions. Briefly, a stem loop primer was
used for reverse transcription of 2 ng of total RNA in two steps
(30min,16 °C;30min,37 °C),followedbyqPCRemployingthe
FAM-TaqMan probe and primers provided. Perfectprobe,
fromPrimerDesign(SouthamptonSO150DJ),wasemployedto
detect DC-SIGN (For, TGTAGGAATGGTCTGGACTAGG;






g of cell lysates were subjected to SDS-PAGE under reducing
conditions and transferred onto an Immobilon polyvinylidene
difluoride membrane (Millipore Corp., Bedford, MA). Protein
detection was performed using the SuperSignal West Pico
chemiluminescent system (Pierce). Antibodies employed were
from Santa Cruz Biotechnology, Inc.: -PU.1 (sc-352); -DC-
SIGN (sc-20081), and -tubulin (sc-58667). Quantity One pro-
gram was used to quantify PU.1 in Fig. 3.
RESULTS
MiR-155 Increases during Maturation of DCs—DC matura-
tion can be induced by several stimuli such as components of
bacteria,viruses,parasites,andcytokines.Lipopolysaccharides,
peptidoglycans, flagellin, CpG motifs, and viral nucleic acids
induceToll-likereceptorsignaling,whichtriggersdendriticcell
maturation. It has been shown previously that most of these
inflammatory stimuli up-regulate miR-155 levels in macro-
phages by activating the NF-B signaling pathway (3, 22). To
determine whether this up-regulation occurs during den-
dritic cell maturation, we exposed monocyte-derived DC to
LPS, which is widely reported to drive DC maturation (23)
FIGURE 1. miR-155 increases during maturation of DCs. A, RNA from LPS
matured dendritic cells (mDC) and untreated DCs (iDC) was collected at dif-
ferent time points and mature miR-155 was determined by microRNA-spe-
cific RT qPCR. Data were normalized with RNU6B. B, protein extracts of the
same samples were subjected to Western blot. PU.1 expression was deter-
minedandproteinconcentrationcontrolledwith-tubulin.C,RNAextracted
for A was also subjected to standard RT qPCR and PU.1 mRNA levels were
quantified, normalizing with ACT1B. Data in A and C represent mean  S.D.
(error bars). These experiments were done on cells from three different
donors, with similar results. A representative one is shown.
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 (supplemental Fig. S1). We then followed the changes in
miR-155 levels over time in these cells, by use of reverse
transcription followed by stem loop-specific quantitative
PCR. During LPS-induced maturation, we could detect
increased differential expression of miR-155 by 6 h, whereas
a maximum value of 136-fold increase was reached by 48 h;
no significant change occurred in the immature DCs over
that time (Fig. 1A).
IthasbeendescribedthatPU.1proteinlevelsdecreaseduring
DC maturation (10). From computer analyses using different
programs that predicted PU.1 as a putative target of miR-155
(24,25),wewonderedwhethertherewasacorrelationbetween
the increase in miR-155 levels and the pattern of expression of
PU.1 over the maturation process. PU.1 protein expression in
maturing DCs was assessed by Western blotting, and we
observed that PU.1 levels decreased over time; levels were
reduced at 12 h, whereas they remained constant in immature
DCs over this time (Fig. 1B). Also, the levels of PU.1 mRNA in
these cells were determined by qPCR. LPS stimulation also
reduced the levels of PU.1 mRNA (Fig. 1C). Thus, miR-155
levels increased during DC maturation, whereas PU.1 protein
and mRNA levels decreased. These data suggested that miR-
155 might play a role during DC maturation, and it raised the
possibility that PU.1 might be targeted by miR-155 during this
process.
miR-155 Directly Targets Human PU.1—Using bioinfor-
matic databases, miR-155 was predicted to target human PU.1






and FADD), MAF and, more recently, miR-155 was demon-
strated to target the 3-UTR of murine PU.1 (4, 22, 27, 28).
To prove, for the first time, a direct link between miR-155
and human PU.1, we performed luciferase reporter assays in
HeLa cells. For this assay, we generated a reporter construct
that expressed a fusion protein between the Renilla luciferase
mRNA and the 3-UTR of PU.1 (pRLTK-WT-PU.1). Also, we
generatedanalternativeconstructinwhichthepredictedseed-
ing region for miR-155 in the 3-UTR of PU.1 was mutated
(pRLTK-MUT-PU.1) (shown in Fig. 2B). This mutation was
decideduponbytheabrogationofthematchbetweenmiR-155
and the 3-UTR of PU.1, as predicted by the RNA-Hybrid pro-
gram (29). HeLa cells were co-transfected with a plasmid that
expressedmiR-155andoneoftheRenillaluciferasefusionplas-
midsdescribed,ortheemptyvector.Itwasfoundthatco-trans-
fection of the plasmid expressing miR-155 reduced the activity
of the wild type 3-UTR of the PU.1 reporter by 85%. The
reporters that did not contain the seeding sequence for miR-
155, both control and mutant exhibited no significant reduc-
tion in their Renilla luciferase activity, when co-transfected
with the miR-155 expressing vector (Fig. 2A).
As a conclusion, our experimental results confirm the target
prediction given by different bioinformatic databases and
establishthathumanPU.1isindeedadirectfunctionaltargetof
miR-155. We also localized the binding region for miR-155 on
the 3-UTR of PU.1, because mutation of the predicted seeding
region abrogated the down-regulation exerted by miR-155.
miR-155-induced Overexpression Down-regulates PU.1 Pro-
tein Levels—During DC maturation, after LPS stimulation,
there is a correlation between the increase in miR-155 levels
andthedecreaseinPU.1(Fig.1).Becauseoftheprofoundinflu-
ence of pro-inflammatory stimuli on gene expression, LPS may
trigger a number of direct or indirect cellular responses that
could lead to a decrease of PU.1 during DC maturation. To
dissect whether there is a link between the presence of
increased levels of miR-155 and the down-regulation of PU.1,
we generated a cellular system in which we could rule out an
effect due to other signaling pathways activated by LPS. To
achieve this, we employed lentiviral vectors containing a
sequence that could be processed into mature miR-155, under
the transcriptional control of the Tetracycline TeT repressor
motif, based on a Tet-on system (30). We stably transduced
THP-1 monocytic cells, thus generating a cell line in which the
expressionofmiR-155isinducedafteradditionofdoxycycline,
atetracyclinederivative,totheculturemedium.Therefore,this
cell line, THP1–155, is able to express miR-155 in the absence
of LPS or other inflammatory stimuli. This allowed us to eluci-
date more clearly the effect of miR-155 on the regulation of
PU.1 in a myeloid cell line.
We compared THP1–155 cells treated or untreated with
doxycycline over the course of 96 h. Then, we determined the
levels of miR-155 during this period, using RT qPCR, as
FIGURE 2. MiR-155 targets PU.1 3 -UTR. Dual luciferase assay was per-
formedonHeLacellstransfectedwithpGL3(normalizingcontrol)andpRLTK
(Control), pRLTK_WT_3UTR_PU1 (WT), or pRLTK_MUT_3UTR_PU1 (Mut).
These plasmids were co-transfected with pCDNA3.1 (Control) or
pCDNA3.1-BIC (miR-155). Normalized Renilla luciferase values were repre-
sentedrelativetothecontrolineachcase.DatarepresentmeanS.D.(error
bars). *, statistically significant, 0.05.
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miR-155 (Fig. 3A) over time, reaching a maximum of 8-fold
induction 96 h after transgene induction, when compared with
the doxycycline untreated, non-induced control.
We then interrogated the system for the expression of PU.1
to establish a link between the expression of miR-155 and the
previously observed reduction in PU.1 protein and mRNA lev-
els in DCs (Fig. 1). We performed PU.1 protein detection by
Western blot and, as expected, when miR-155 was overex-
pressed following doxycycline treatment, the levels of PU.1
were clearly reduced, reaching the minimum expression in the
doxycycline-treated THP1–155 after 96 h (Fig. 3B). PU.1 pro-
tein levels were reduced by approximately 85% at this time
point, which correlated with the maximum value of miR-155,
an 8-fold induction, both compared with time 0 h. To learn
more about the mechanism of action of miR-155 on the regu-
lationofPU.1,wedeterminedthemRNAlevelsofPU.1overthe
sametimecourse.WequantifiedtheexpressionofPU.1mRNA
by RT qPCR, comparing doxycycline-treated with untreated
THP1–155 cells. Fig. 3C shows that the increase of miR-155 in
THP1–155 cells does not affect the expression levels of PU.1
mRNA. This result suggests that miR-155 might be blocking
thetranslationofPU.1mRNA,acommonmechanismofaction
of microRNAs.
Thus, aspects of DC maturation that are related to miR-155
are mimicked by THP1–155 cells. In this regard, an increase of
miR-155 over time results in a decrease in PU.1 protein levels.
Thesedatademonstrateadirectlinkbetweentheexpressionof
miR-155 and the protein expression levels of the transcription
factor PU.1.
miR-155 Expression Down-regulates DC-SIGN Levels in
THP1–155 Cells—DC-SIGN is a C-type lectin that mediates
bindingandinternalizationofviral,bacterial,andfungalpatho-
gens by myeloid dendritic cells. This is an important role of
immature DCs, as they act as immune sentinels sampling their
surroundings in search for pathogen antigens. Also, it has been
reported that DC-SIGN triggers intracellular signals that mod-
ulatedendriticcellmaturation(31).DC-SIGNisreportedtobe
down-regulated during the maturation of dendritic cells (10).
After phagocytosis and activation, mature dendritic cells show
a significantly reduced capacity to detect and ingest antigens,
which is reflected by down-regulation of DC-SIGN. The tran-
scriptional down-regulation of DC-SIGN in DC maturation
seems to depend on the concurrent decrease of PU.1 (10). Tak-
ing these previous studies into consideration, we investigated
whether miR-155 could be regulating DC-SIGN levels during
the maturation process by targeting PU.1.
We used THP1–155 in which we could control miR-155
expression and down-regulate PU.1. It has already been
reported that THP-1 cells could be differentiated into dendrit-
ic-like cells, sharing some inherent functions such as pathogen
binding, T cell stimulation, and DC-SIGN down-regulation
after LPS treatment (32). Also, THP1 cells have been shown to
overexpress miR-155 in response to LPS treatment (3). To
determine whether the presence of miR-155 and the subse-
quent down-regulation of PU.1 could affect the expression of
DC-SIGN, we cultured THP1–155 cells, in the presence or
absence of doxycycline, and determined the levels of DC-SIGN
protein by Western blot after 24 and 48 h. In concordance with
the expected outcome, the induction of miR-155 by doxycy-
cline reduced the levels of DC-SIGN to 50% when compared
with untreated cells (Fig. 4A, upper panel). This result was fur-
ther confirmed by flow cytometry, where the membrane
expression of DC-SIGN was similarly reduced when cells over-
expressed miR-155 (Fig. 4B). DC-SIGN mRNA levels were
quantified to elucidate whether the effect of miR-155 was tak-
ing place at the mRNA expression level. Cells overexpressing
miR-155 expressed lower levels of DC-SIGN mRNA than the
untreated control (Fig. 4C). A control experiment was per-
formed to show that this effect was indeed due to miR-155.
THP1–155 cells were transfected with oligonucleotide anti-
miR-155(oranirrelevantanti-miRcontrol).Thiswasexpected
to block the effects of miR-155 overexpression, which would
FIGURE3.THP1–155cellsoverexpressingmiR-155showeddown-regula-
tionofPU.1proteinexpression.A,THP1–155cellsweretreatedornotwith
doxycycline (DOX) to de-repress or not the expression of the miR-155 trans-
gene, respectively. Cells were collected at different time points, and sub-
jected to RNA extraction. RNA from these samples was subjected to specific
microRNA RT qPCR, and miR-155 levels were quantified. RNU6B was
employedfornormalizationpurposes.B,proteinextractsfromthesamesam-
plesweresubjectedtoWesternblotting,andPU.1levelsweredetermined.As
a control, -tubulin was also detected in the same blot. Values represent
percentageofPU.1normalizedagainst-tubulinandcomparedwithcontrol.
C, the same RNA extracts were also used to perform standard RT qPCR, to
detect PU.1 mRNA levels. Values were normalized against ACT1B. This figure
shows one representative experiment of three. Data in A and C represent
meanS.D.(errorbars).DifferencesinB(DoxversusDox),notsignificant.
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 establish that they were due solely to the presence of miR-155.
Inthisexperiment(supplementalFig.S1)weconfirmedthatwe
could rescue the expression of DC-SIGN with an antagonist to
miR-155. We confirmed in THP-155 cells that when miR-155
was overexpressed PU.1 protein levels were down-regulated,
and that PU.1 expression was not affected at the mRNA level
(Fig. 4, A, lower panel, and D).
Overall, we have demonstrated that THP1–155 cells are a
good model in which to investigate the effect of miR-155 on
DC-SIGNandPU.1regulation.Wehaveshownthat,asinmat-
uration of monocyte-derived DCs (10), so in THP-155 cells, an
increase in miR-155 correlates with down-regulation of DC-
SIGN, at both the mRNA and protein levels.
TheTranscriptionalActivationofDC-SIGNPromoterIsReg-
ulated by miR-155 via PU.1—Both PU.1 and DC-SIGN appear
to be regulated by miR-155 in THP1–155 cells. However, DC-
SIGN mRNA is down-regulated by the presence of miR-155,
whereas PU.1 mRNA remains unaltered. These results suggest
a different regulatory mechanism for both proteins; whereas
DC-SIGN could be affected at the transcriptional level, PU.1
seems to be regulated by miR-155 at the translational level.
Interestingly, PU.1 has been shown to regulate DC-SIGN
expression through binding of two
motifs in its promoter region, both
in dendritic cells and THP1 cells
(10). Based on this finding, we
hypothesized that miR-155 was
affecting DC-SIGN levels indirectly
through down-regulation of PU.1
and the subsequent decrease in the
transcriptional activity of the
DC-SIGN promoter. To test this,
we employed a luciferase-based
reporter construct in which tran-
scriptional activity is controlled by
the proximal DC-SIGN promoter
(10). We transfected this construct
intoTHP1–155cells,whichoverex-
pressed miR-155 when treated with
doxycycline. The results showed
that overexpression of miR-155
reduced the activity of the DC-
SIGN-luciferase reporter; the de-
crease was similar to that found in
previousassaysofDC-SIGNprotein
and mRNA levels (Fig. 5). To inves-
tigate the role of PU.1, we co-trans-
fected the cells with expression vec-
tors coding for PU.1. In both
doxycycline-treated and untreated
cells, overexpression of PU.1 in-
duced a similar relative luciferase
activity in the DC-SIGN reporters,
which was clearly independent of
the presence of miR-155. Thus, the
miR-155-mediated suppression of
the DC-SIGN promoter was effec-
tively rescued by the presence of
PU.1.Ofnote,thePU.1cDNAsequenceclonedintotheexpres-
sion vector does not contain the 3-UTR of PU.1 and therefore
does not contain the target seeding region for miR-155 (Fig. 2).
This presumably renders the expressed PU.1 mRNA resistant
to the blocking activity of miR-155. Interestingly, co-transfec-
tion of a PU.1 construct containing the 3-UTR was not able to
efficiently rescue expression of the DC-SIGN promoter. Alto-
gether,theseresultsindicatethatmiR-155regulatestheexpres-
sion of DC-SIGN at the transcriptional level, and that this
regulation is related to the 3-UTR-dependent down-regula-
tion of PU.1.
Pathogen Binding Capacity Is Affected by miR-155 Over-
expression—Finally,thefunctionalconsequencesoftheexpres-
sion of miR-155 and subsequent down-regulation of DC-SIGN
were investigated. DC-SIGN recognizes pathogens by binding
to pathogen-specific carbohydrate residues and is mainly
expressedinDCsandalternativelyactivatedmacrophages(32).
Importantly, the binding activity of DC-SIGN seems to be
involved in determining the immune response triggered by the
presence of certain pathogens (33, 34). To determine the effect
of miR-155 on the expression of DC-SIGN in the membrane of
DCs, we transfected mature DCs with anti-miR-155 to inhibit
FIGURE4.DC-SIGNlevelsaredown-regulatedbymiR-155expressioninTHP1–155cells.A,THP1–155cells
were treated or not with doxycycline (DOX), to de-repress miR-155 inducible expression, respectively. Cells
were collected at different time points and protein extracts subjected to Western blot. DC-SIGN and PU.1
protein expression was determined, as well as -tubulin, as control. B, these cells were subjected to flow
cytometryandDC-SIGNandgraphsshowpercentageofpositivepopulation(%)andmeanfluorescenceinten-
sity (MFI). C and D, RNA from the same samples was subjected to standard RT qPCR. DC-SIGN (C) and PU.1 (D)
mRNAlevelswerequantifiedandnormalizedagainstACT1B.Shownisonerepresentativeexperimentofthree.
Data in C and D represent mean  S.D. (error bars). Differences in D (Dox versus Dox), not significant.
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 the activity of miR-155. Then, we incubated the DCs trans-
fected with anti-miR-155 or anti-miR-Control with a specific
anti-DC-SIGN antibody and analyzed the cells by flow cytom-
etry. Fig. 6A shows that the expression of DC-SIGN on DCs
increases when miR-155 is inhibited by anti-miR-155. This
result is in accordance with the decrease in total and mem-
brane-expressed protein as well as in the mRNA expression
observed previously in THP1–155 cells, when miR-155 was
overexpressed (Fig. 4). A parallel control experiment revealed
that transfection with anti-miR-155 significantly reduced the
level of miR-155 in LPS-treated DCs (supplemental Fig. S3).
We then hypothesized that the increase in DC-SIGN
observed in the membrane of DCs when miR-155 levels were
reduced, could affect their capacity to bind pathogens. To test
this hypothesis, we employed C. albicans as a model pathogen
bound by DC-SIGN (13), and performed a pathogen binding
assay. The fungi were heat inactivated, labeled with propidium
iodide as described under “Experimental Procedures,” and co-
incubated with DCs (transfected with anti-miR-155 or anti-
miR-Control). After several washes, cells binding labeled C.
albicans were analyzed using flow cytometry. DCs transfected
with anti-miR-155 showed an increased binding capacity for
C. albicans (Fig. 6B) when compared with anti-miR-Control-
transfected DCs. Furthermore, blocking DC-SIGN with a spe-
cific anti-DC-SIGN antibody reduced binding to C. albicans,
suggesting the participation of DC-SIGN in this process (sup-
plemental Fig. S4). We then performed binding experiments
with labeled HIV-1 protein gp120. gp120 protein has been
showntobindDC-SIGN,whichiscrucialinthetrans-infection
of HIV-1 (16). As expected, the anti-miR-155 augmented the
binding capacity of mature DCs for gp120 (Fig. 6C). Taken
together, these data show that the increase of miR-155 during
DC maturation reduces the capacity of the cells to bind patho-
gens by DC-SIGN down-regulation.
DISCUSSION
Intheirnormalperipherallocation,themainfunctionofDCs
is to sample their surroundings, detecting pathogens and for-
eign molecules. They express a variety of pathogen binding
molecules such as DC-SIGN and are actively endocytic. After
activation, the DC migrates to the lymph nodes to present the
foreignantigentoTcells.DuringthismigrationtheDCunder-
goes maturation, down-regulating endocytic activity and
pathogen binding molecules, whereas up-regulating molecules
such as major histocompatibility complex class II that will be
involved in antigen presentation. In this study we have shown
that miR-155 regulates the levels of DC-SIGN at the transcrip-
tionallevel,indirectly,throughdirecttargetingoftranscription
factor PU.1.
The reciprocal relationship between increased miR-155 lev-
els and reduced PU.1 expression during LPS induced DC mat-
uration(Fig.1)suggestedalinkorinteractionbetweenmiR-155
and PU.1. Searches of computer databases predicted that the
recognitionsequenceformiR-155waspresentinthe3-UTRof
PU.1. By use of a reporter assay in which expression of Renilla
luciferase was driven by the 3-UTR of PU.1 (Fig. 2) we have
shownthathumanPU.1isindeedadirecttargetformiR-155.A
similar observation has been made in murine systems although
thesequencesdifferbetweenthespecies.Moreover,employing
the program RNA Hybrid (29), we show a difference in the
predicted secondary structure of the complex of miR-155:PU.1
(supplemental Fig. S5), which is known to be key in microRNA
targeting. We also mapped the binding region for miR-155,
which coincides with the one predicted using several bioinfor-
matic tools. It consists of a seeding region of 9 bases, which is
stronger than those of other targets studied so far, which are in
the range of 6–8 bases (4, 27). This region is likely to play an
important role in PU.1 regulation in different contexts such as
hematopoietic development and myeloid disorders (9, 35–37).
Intriguingly, it has recently been demonstrated that miR-155
overexpressionislinkedtoamyeloiddisorder(38),whichcould
be related to the ability of miR-155 to target PU.1.
Apart from its role in hematopoietic development, PU.1
playsanimportantroleindendriticcells,asdescribedinseveral
reports (9, 10, 39). Furthermore, it is well established that PU.1
is able to regulate the levels of DC-SIGN (10). PU.1 is down-
regulatedduringmaturationofDCs,andthisisassociatedwith
reduced levels of DC-SIGN. To investigate a possible link
between miR-155 and the maturation-related decrease in DC-
SIGN expression, we generated a system in which THP1 cells
were able to express miR-155 in an inducible way, isolating its
effect from other pathways activated during DC maturation.
We chose THP1 cells as they can regulate DC-SIGN and miR-




result mimics that in DCs, where PU.1 decreased during matu-
FIGURE 5. The transcriptional activity of DC-SIGN promoter decreases
when miR-155 is overexpressed. THP1–155 cells were treated or not with
doxycycline (DOX) for 96 h, to allow for miR-155 to be expressed or to main-
tain the repression, respectively. Cells were then transfected with pRLTK-Re-
nilla, as control for transfection, and a reporter containing the proximal pro-
moterofDC-SIGN(pCD209–468pXP2).Thesecellswereco-transfectedwith
expression vectors pCDNA3.1 (Control), pCDNA3.1_PU.1 (PU.1), or
pCDNA3.1_PU.1_3UTR. Luciferase values were determined and normalized
against Renilla luciferase. Data represent mean  S.D. (error bars). *, statisti-
cally significant 0.05 compared with Dox control. **, statistically signifi-
cant(0.05)whencomparedwithDox/pCDNA3,1_PU.1_3UTR-transfected.
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 ration, whereas miR-155 increased (Fig. 1). However, there
appears to be a difference in the regulation of PU.1 mRNA in
maturing DCs and induced THP1–155 cells. In THP1–155,
PU.1 mRNA levels are stable (Fig. 3), which suggests that miR-
155isblockingPU.1mRNAtranslation,ratherthanpromoting
its cleavage. During DC maturation, however, PU.1 mRNA is
down-regulated (Fig. 1). A possible explanation could lie in the
different levels of miR-155 expression attained by the two cell
types (with a similar basal expression of miR-155); the expres-
sion of miR-155 in THP1–155 reaches a maximum of 8-fold
over the basal levels, whereas mature DCs have 130 times
more miR-155 than the immature ones. Thus, it is conceivable
that when miR-155 reaches certain levels of overexpression, it
could promote cleavage of PU.1 mRNA as well as blocking its
translation. Other explanations, not exclusive of the previous
one, could involve either other microRNAs, or possibly, yet to
be described pathways triggered by LPS, which might affect
PU.1 mRNA expression at the transcriptional level.
We found that the levels of DC-SIGN mRNA and protein
were down-regulated in THP1–155 cells that overexpressed
miR-155 (Fig. 4). These results were consistent with our initial
hypothesis that DC-SIGN is regulated at the transcriptional
level by PU.1, and that down-regu-
lation of PU.1 by miR-155 would
lead to a decrease in the transcrip-
tional expression of DC-SIGN. By
using a reporter containing the
DC-SIGN promoter fused to the
luciferase gene, we showed that
thepromoteractivityofDC-SIGNis
down-regulated when miR-155 is
overexpressed. Furthermore, this
down-regulation is rescued when a
vector encoding for PU.1 but lack-
ing the 3-UTR, is co-transfected
into the cells (Fig. 5). The experi-
ments shown in Figs. 4 and 5
demonstrate the indirect effect of
miR-155 on the transcriptional reg-
ulation of DC-SIGN, through tar-
geting PU.1.
Having shown how, as DCs
mature, miR-155 down-regulates
expression of PU.1, which in turn
resultsinreducedexpressionofDC-
SIGN, we then predicted that this
should result in impaired recogni-
tion and binding of pathogens by
DCs. Our data (Fig. 6) show that
miR-155 levels are correlated with
the ability of the cell to bind patho-
gens (C. albicans and HIV-1 gp120
protein). To test this hypothesis we
employed mature DCs and showed
that blocking the activity of
miR-155 by transfecting an anti-
miR-155 oligonucleotide, levels of
DC-SIGN were increased and there
was augmented binding of pathogens by DCs. Thus, the
increase in miR-155 levels has a functional consequence, with
an important physiological role in DCs.
The link between miR-155 and the pathogen binding ability
of DC-SIGN could have a role in determining the immune
response against certain pathogens or in the ability of certain
pathogens to infect the humans. It has been reported that
SIGNR1 (human DC-SIGN orthologue in mouse) knock-out
mice have a more Th1-dominated immune response against
Mycobacterium tuberculosis when compared with WT mice,
suggesting a role for SIGNR1 in the Th1/Th2 balance of the
immuneresponse.Inagreementwiththis,thereisalsoreported
evidenceforanimportantroleofDC-SIGNduringtuberculosis
in humans (40). Thus, DC-SIGN-mediated pathogen binding
may have important consequences on the immune responses
against the tubercle bacilli in the infected host.
The dramatic increase of the levels of miR-155 (up to 130-
fold, Fig. 1) during DC maturation, not previously described,
adds this process to others regulated by miR-155 (4, 5). Impor-
tantly,DCsareimplicatedinthedelicatebalanceofTcellpolar-
ization and the maturing DC in response to different microbial
productscouldhaveadecisiveinfluence(41).Itistantalizingto
FIGURE 6. Pathogen binding capacity of DCs is affected by miR-155. DCs were transfected with either
oligonucleotide anti-miR-155 or anti-miR-Control, and Cy3 labeled pre-miR-Control. A, DC-SIGN membrane
expression in transfected cells was assessed by flow cytometry and presented as graphs showing percentage
of positive population (%) and mean fluorescence intensity (MFI). Overlay of both graphs is also shown. Cell
number is normalized as percentage of maximum (FlowJo). B, these cells were assayed for their binding
capacity to labeled C. albicans conidia. The binding ability of the cells was determined by flow cytometry and
presented as in A. C, DCs transfected as previously described were subjected to binding assays employing
HIV-1 recombinant gp120-fluorescein isothiocyanate (FITC). Binding capacity was determined through flow
cytometry and expressed as inA. The flow cytometry data in this figure correspond to a representative exper-
iment out of three independent repeats. PI, propidium iodide.
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 hypothesize that the effect of miR-155 on DC-SIGN and the
PU.1 expression described here could affect the balance of the
immune response against pathogens. Thus, miR-155 in DCs
could contribute to driving Th1 polarization, hence playing an
important role in the initial steps of infection. In addition to
effects on the immune response, miR-155 could have a more
obvious impact on the infection process of certain pathogens.
Our results could have important consequences in infection by
HIV-1,andmightsuggestaroleformiR-155inmakingsubjects
more or less susceptible to infection. Interestingly, there are
severalstudiesreportingthepossibleuseofDC-SIGNblocking
agents that aim to stop HIV-1 infection (42–45). Thus, miR-
155 could be a new therapeutic target that could help prevent
entrance of HIV-1 through binding of DC-SIGN.
In conclusion,ourstudyrevealsthatmiR-155hasanimportant
role during DC maturation, inhibiting the expression of the tran-
scription factor PU.1 and thus decreasing the levels of DC-SIGN
and the pathogen binding ability of the cells. miR-155 could be of
importance in several infectious diseases, and may contribute to
susceptibility to infection and invasion by a range of pathogens.
Furthermore, our findings suggest an additional explanation for
how miR-155 is involved in modulating the Th1/Th2 balance,
namely through controlling the maturation of DCs.
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Macrophages  play  a  central  role  in  the 
balance and efficiency of the immune response 
and  are  at  the  interface  between  innate  and 
adaptive  immunity.  Their  phenotype  is  a 
delicate equilibrium between the M1 (classical, 
pro-Th1) and M2 (alternative, pro-Th2) profiles. 
This balance is regulated by cytokines such as 
interleukin  13  (IL-13),  a  typical  pro-M2-Th2 
cytokine  that  has  been  related  to  allergic 
disease  and  asthma.  IL-13  binds  to  IL-13 
Receptor  α α α α1  (IL13Rα α α α1),  a  component  of  the 
Type II IL- 4Receptor, and exerts its effects by 
activating  the  transcription  factor  Signal 
Transducer  and  Activator  of  Transcription  6 
(STAT6) through phosphorylation. MicroRNAs 
are short (~22nt) inhibitory non-coding RNAs 
that  block  the  translation  or  promote  the 
degradation of their specific mRNA targets. By 
bioinformatics’  analysis  we  found  that 
microRNA 155 (miR-155) is predicted to target 
IL13Rα α α α1.  This  suggested  that  miR-155  might 
be  involved  in  the  regulation  of  the  M1/M2 
balance  in  macrophages  by  modulating  IL-13 
effects.  Mir-155  has  been  implicated  in  the 
development of a healthy immune system and 
function  as  well  as  in  the  inflammatory  pro-
Th1/M1 immune profile. Here we have shown 
that in  human macrophages miR-155  directly 
targets  IL13Rα α α α1  and  reduces  the  levels  of 
IL13Rα α α α1  protein  leading  to  diminished 
activation  of  STAT6.  Finally  we  also 
demonstrate  that  miR-155  affects  the  IL13-
dependent regulation of several genes (SOCS1, 
DC-SIGN,  CCL18,  CD23  and  SERPINE) 
involved in the establishment of a M2/pro-Th2 
phenotype in macrophages. Our work shows a 
central role for miR-155 in determining the M2 
phenotype in human macrophages.  
 
Macrophages are key players at the interface 
between innate and adaptive immunity. They arise 
from  circulating  monocytes  that  are  recruited  to 
tissues  by  different  stimuli.  They  work  as 
phagocytes  and  antigen  presenting  cells, 
promoting  inflammation  and  its  resolution. 
Macrophages present a wide range of phenotypic 
profiles and defence mechanisms depending on the 
tissue context and the stimuli present (pathogens, 
cytokines, apoptotic cells…). They are generally 
classified  into  two  main  types:  M1  (classically 
activated)  and  M2  (alternatively  activated) 
macrophages.  Classically  activated  (M1) 
macrophages are a result of an exposure to pro-Th1 
cytokines,  while  alternatively  activated  (M2) 
macrophages  are  generated  in  a  pro-Th2 
environment  (1).  Classically  activated 
macrophages  are  specialised  in  defence  against 
intracellular pathogens and upon stimulation with 
pro-inflammatory  stimuli  (interferon-γ  or  LPS), 
they  promote  inflammation,  causing  tissue 
damage.  By  contrast,  alternative  activation  of 
macrophages  is  induced  by  a  broader  range  of 
stimuli including interleukin 4 (IL-4), interleukin 
13  (IL-13),  interleukin  10  (IL-10)  or 
glucocorticoids  and  are  specialised  in  defence 
against  extracellular  pathogens,  promoting  tissue 
repair  and  the  resolution  of  the  inflammatory 
process (2). Regardless of this classification, one 
of  the  most  remarkable  characteristics  of 
macrophages is their plasticity and heterogeneity, 
depending on the specific task carried out. This is 
reflected by their ability to reverse their phenotype 
and reprogram their M1/pro-Th1 and M2/pro-Th2 
gene  expression  profiles,  presenting  in-between 
phenotypic  profiles  and  a  constituting  a 
heterogeneous  population  (1).  The  present  study 
has  focused  on  alternatively  activated 
macrophages generated by IL-4 and IL-13 (2). 
Interleukin  13  (IL-13)  is  a  typical  Th2  type 
cytokine  which,  together  with  IL-4,  drives  and 
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modulates the immune response. First described as 
a  Th1  down-regulator  (3),  its  role  as  an  active 
immune  mediator  has  been  described  and 
distinguished from those of IL-4 by several studies 
(4-7).  Interleukin  13  is  a  key  cytokine  in  the 
defence against gastrointestinal nematodes (8) and 
plays a central role in some chronic inflammatory 
diseases  such  as  asthma  and  ulcerative  colitis 
(9,10). Interestingly, and underscoring the role of 
IL-13 in asthma, mice lacking the IL-13 receptor 
 alpha  1  chain  (IL13Rα1),  showed  a  complete 
absence  of  allergen-induced  airway  hyper-
reactivity and mucus hypersecretion (6). IL13Rα1 
is  an  essential  component  of  the  Type  II  IL-4 
receptor, which consists of heterodimers of IL4Rα 
and IL13Rα1 chains. Both IL-4 and IL-13 bind to 
the Type II receptor, but only IL-4 can bind to the 
Type I receptor. Therefore, the binding of IL-13 
depends  solely  on  the  presence  of  IL13Rα1 
(11,12).  Engagement  of  these  receptors  leads  to 
phosphorylation and activation of Janus Tyrosine 
Kinases (JAK) proteins, believed to be bound to 
these  cytokines  receptors  in  unstimulated  cells. 
The  active  phospho-JAK  proteins  phosphorylate 
the  IL4Rα chain,  providing  docking  sites  for 
STAT6.  Once  bound  to  the  receptor,  STAT6  is 
also  phosphorylated  by  JAKs,  which  causes  its 
activation,  dimerization  and  translocation  to  the 
nucleus,  where  it  exerts  its  transcriptional  roles 
(13). 
Since  their  relatively  recent  discovery  (14), 
miRNAs  have  been  shown  to  play  important 
biological  roles  in  different  contexts:  during 
development,  cell  differentiation  and  immune 
regulation, and also in pathologies such as cancer 
(15-17). They are small non-coding RNAs of ~22 
nt (nucleotides) that regulate gene expression upon 
binding to the 3’UTRs (UnTranslated Regions) of 
their target mRNAs (18). MicroRNAs are firstly 
transcribed  as  immature  pri-miRNAs  which  are 
processed in the nucleus into ~70nt hairpin pre-
miRNAs  by  Drosha  proteins.  Pre-miRNAs  are 
then  exported  to  the  cytoplasm  where  Dicer 
proteins  process  them  into  mature 
miRNA*::miRNA complexes. The leading strand 
,miRNA, is loaded into the RISC complex where it 
guides  Argonaute  proteins  towards  their  target 
mRNAs (19). The selectivity of miRNA action is 
given by the nucleotides 2 to 7 at their 5’ end (the 
“seed region”) that pairs to its complementary site 
in  the  targeted  3’UTR  by  Watson-Crick 
interactions  directing  the  RISC  action  (18).  The 
inhibitory  activity  of  microRNAs  ensues  by 
blocking the target mRNA translation into protein 
and/or the degradation of the mRNA (20).  
MicroRNAs  have  proven  to  be  key  in 
modulating  the  immune  system  (21).The 
microRNA  focus  of  this  study,  microRNA-155 
(miR-155),  has  been  extensively  studied  in 
immunology  and  inflammation  (21-23).  Two 
different  knock  out  models  have  been  generated 
showing  that  mice  lacking  miR-155  present  an 
abnormal immune function with aberrant B and T 
cell  repertoires  and  defective  antigen  presenting 
cells (16,24). Several reports present miR-155 as a 
key player in B cell responses (17) and in dendritic 
cell  function  (25,26).  Moreover,  miR-155 
expression levels increase during inflammation in 
classically  (pro-Th1)  activated  macrophages 
(21,27) and has been clearly linked to a pro-Th1 
bias, since knockout mice for miR-155 have a pro-
Th2 unbalanced T cell repertoire (16). Therefore, it 
is  well  established  that  miR-155  plays  a  central 
role  not  only  in  the  development  of  a  healthy 
immune system but also as a pro-Th1 microRNA. 
Using  in  silico  analysis  (miRanda  (28), 
RNAHybrid  (29),  PITA  algorithm  (30))  we 
identified  IL13Rα1  as  a  putative  target  of  miR-
155. We have shown for the first time that indeed, 
miR-155  down  regulates  the  effects  of  the  Th2 
cytokines  IL4  and  IL13,  providing  a 
straightforward  link  between  miR-155  and  the 
Th1/Th2  balance.  Our  work  shows  that  miR-155 
directly  targets  IL13Rα1  3’UTR  reducing  the 
levels of IL13Rα1 protein. By doing so, miR-155 
affects  the  IL-4  and  IL-13  dependent 
phosphorylation of STAT6. We finally show that 
miR-155 levels modulate the response of human 
macrophages to IL-13 leading to a change in their 
genetic profile. Therefore, miR-155 contributes to 
the  Th1/Th2  equilibrium,  favouring  a  pro-
Th1/classical  activation  of  macrophages  by 





Cell culture. THP1-155 cells. This cell line was 
generated as described before (26). Briefly, THP-1 
cells were doubly transduced with a doxycycline-
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elsewhere  (31),  in  which  miR-155  transgene  is 
under  the  control  of  a  tetracycline  response 
element. Lentiviral vectors were kindly provided 
by Prof. Didier Trono and cells were maintained in 
RPMI  10%FBS  (GIBCO).  To  induce  miR-155 
expression 2.5 µg/ml doxycycline (SIGMA) was 
added  or  not  to  the  medium  and  renewed  daily 
over  96h  of  culture.  Cytokine  treatments  were 
performed  as  following:  firstly,  cells  were 
incubated  or  not  with  doxycycline  for  96h  and 
then they were starved for an extra 12h period and 
then stimulated or not with IL-4 (Immunotools) or 
IL-13 (R&D). Cell extracts were collected when 
indicated, after the treatment. 
HeLa. Cells were maintained in DMEM 10% 
FBS.  
Macrophages: Monocytes were obtained from 
buffy  coats  from  healthy  donors  over  a  density 
gradient  (Ficoll-Paque™  PLUS,  GE  Healthcare) 
following  manufacturer’s  instructions.  Briefly, 
PBMCs  (Peripheral  Blood  Mononuclear  Cells) 
were isolated by centrifugation over Ficoll-Paque 
and  monocytes  were  isolated  from  the  PBMC 
fraction  using  CD14  magnetic  microbeads 
(Miltenyi). Cells were maintained in RPMI 10% 
FBS  supplemented  with  500U/ml  GM-CSF 
(Immunotools) to allow differentiation. 
Vector  constructs.  pCDNA  BIC:  the  genomic 
region  encompassing  miR-155  was  cloned  into 
pCDNA  3.1  expression  vector  as  previously 
described (26).  
IL13Rα1 3’UTR was amplified using plasmid 
DNA  (HmiT009700-MT01,  gene  Copoeia)  as 
template  and  the  following  primers: 
IL13RA1_3’UTR_FOR  GGC  TGT  TAG  GGG 
CAG TGG AG and IL13RA1_3’UTR_REV CAG 
AGC CTT GGC TGG CTG G. The product was 
cloned  in  pCR2.1  TOPO  TA  (Invitrogen),  from 
where  it  was  removed  using  BamHI/NotI.  After 
blunt ending with Klenow DNA polymerase, the 
product  was  cloned  into  NotI  site  in  pRLTK 
(Promega),  this  construct  named  hence  forth 
pRLTK__WT_3´UTR_IL13RA1.  
Mutagenesis  was  performed  on 
pRLTK__WT_3´UTR_IL13RA1  using 
QuickChange  Site  Directed  Mutagenesis 
(Stratagene)  following  manufacturer’s 
instructions.  For 
pRLTK_MUT1_3´UTR_IL13RA1  we  used  the 
primers IL13RA1 3’UTR MUT1FOR: CTG CTA 
CTC AAG TCG GTA CCA CTG TGT CTT TGG 
TTT GTG CTA GGC CCC and IL13RA1 3’UTR 
MUT1REV:  GGG  GCC  TAG  CAC  AAA  CCA 
AAG  ACA  CAG  TGG  TAC  CGA  CTT  GAG 
TAG  CAG.  In  the  case  of 
pRLTK__MUT2_3´UTR_IL13RA1  the  primers 
used  were  IL13RA1  3’UTR  MUT2FOR  CCA 
TGT GAG GGT TTT CAG GGC CGA TAT TTG 
TGC  ATT  TTC  TAA  ACA  G  and  IL13RA1 
3’UTR MUT2 REV CTG TTT AGA AAA TGC 
ACA  AAT  ATC  GGC  CCT  GAA  AAC  CCT 
CAC ATG G. Normalization was performed using 
pGL3 (Promega). 
RT-qPCR.  Total  RNA  was  extracted  using  TRI 
Reagent  (Ambion).  Reverse  transcription  was 
performed  using  High  Capacity  cDNA  Reverse 
Transcription  Kit  (Applied  Biosystems). 
MicroRNA  detection  was  performed  using 
TaqMan  MicroRNA  Assays  (Applied 
Biosystems).  For  Real  Time  PCR  (qPCR)  we 
employed TaqMan® Universal PCR Master Mix, 
No  AmpErase®  UNG  in  a  7900HT  Fast  Real-
Time  PCR  System  machine  (both  from  Applied 
Biosystems).  IL13RA1  qPCR  detection  was 
performed using Perfect Probe from PrimerDesign 
(Southampton SO15 0DJ) and normalized against 
GAPDH  from  the  same  manufacturer.  Genes 
assayed  in  the  IL-13/STAT6  pathway  were 
TaqMan®  Gene  Expression  Assays  (Applied 
Biosystems). 
Western  Blotting.  Total  protein  lysates  were 
subjected  to  SDS-PAGE  under  reducing 
conditions  and  transferred  onto  an  Immobilon 
polyvinylidene
  difluoride  membrane  (Millipore 
Corp., Bedford, MA). Antibodies used were: anti 
IL13Rα1 (sc-27861, Santa Cruz Biotechnology); 
anti STAT6 (#9362, Cell Signalling Technology); 
anti  Phospho-STAT6  (#9361,  Cell  Signalling 
Technology)  and  anti  beta  Actin  antibody  - 
Loading Control (ab8227, abcam). 
Transfections.  To  determine  direct  targeting  of 
IL13Rα1  by  miR-155,  constructs 
pRLTK_WT_3´UTR_IL13RA1, 
pRLTK_MUT1_3´UTR_IL13RA1  or 
pRLTK_MUT2_3´UTR_IL13RA1  were 
transfected  into  HeLa  cells  employing  LT1 
Reagent  (Mirus)  following  manufacturer’s 
instructions. pCDNA BIC or control pCDNA 3.1 
empty  vector were co-transfected to check miR-
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(Promega)  was  used  as  normalizing  vector. 
Luminometry was performed using Dual-Glo kit 
(Promega).  Experiments  were  performed  three 
times  in  triplicates.  Statistical  differences  were 
determined  using  Student’s  t  test  and  GraphPad 
Prism software. 
In  order  to  reduce  the  levels  of  miR-155  in 
primary  macrophages,  100nM  Anti-miR-155 
Inhibitor  or  Anti-miR  Inhibitors—Negative 
Control # (Applied Biosystems) were transfected 
in  human  monocytes  at  day  0  as  described 
previously (26). Briefly, cells were plated onto 96 
well flat bottom plates at a cell density of 5 10
5 
cells/ml with GM-CSF and oligos were added at a 
final  concentration  of  100nM  and  then  kept  in 
culture. On day 3, IL-13 was added or not with a 
renewal dose of GM-CSF, and 24h later RNA was 




MiR-155 directly targets IL13Rα α α α1. 
By  performing  bioinformatic  analysis 
(miRanda,  RNAHybrid,  PITA  algorithm) 
IL13Rα1 was found to have two putative binding 
sites for miR-155 in the 3’UTR and hence, was 
predicted to be a direct target for miR-155 (Fig.1). 
Both  miR-155-IL13RA1-3’UTR  pairs  are  shown 
in  supplement  Fig.  S1  and  their  free  energy  is 
within the range of validated miRNA-target pairs 
(32). Site 1 is located between nucleotides 1049 
and 1071 of the 3’UTR (seeding region is a 7mer) 
and  site  2  between  nucleotides  1399  and  1424 
(seeding  region  is  an  8mer  that  includes  a  G:U 
wobble pair). The direct targeting by miR-155 of 
IL13Rα1,  a  component  of  the  Type  II  IL-4 
receptor,  could  provide  a  crucial  link  between 
miR-155 and its role as “pro-Th1 microRNA”: by 
reducing signaling via the Type II IL-4 receptor 
miR-155  would  reduce  the  ability  of  a  cell  to 
respond  to  the  classical  pro-Th2  cytokines  IL-4 
and IL-13.  In order to test IL13Rα1 as a direct 
target for miR-155 we employed a dual luciferase 
assay in HeLa cells. For this purpose the 3’UTR 
sequence  of  IL13Rα1  harbouring  the  predicted 
binding  sites  for  miR-155  was  cloned  into  the 
renilla-luciferase  reporter  vector  pRLTK  (named 
pRLTK_WT_3’UTR_IL13RA1).  To  test  the 
contribution  of  the  predicted  binding  sites  for 
miR-155  action,  each  site  was  mutated  by  site 
directed mutagenesis. Mutations (shown in Fig.1) 
were  designed  according  to  the  predicted 
abrogation  of  miR-155  binding  using 
bioinformatics (RNAHybrid). The constructs were 
named pRLTK_MUT1_3’UTR_IL13RA1 (mutant 
in  site  1)  and  pRLTK_MUT2_3’UTR_IL13RA1 
(mutant in site 2). Co-transfection of each renilla-
luciferase construct with an expression vector for 
miR-155 (pCDNA BIC) allowed determination of 
the  effects  of  this  microRNA  on  the  3’UTR  of 
IL13Rα1  as  well  as  mapping  its  binding.  When 
miR-155  was  co  transfected  with  the  reporter 
construct that harboured the wild type 3’UTR of 
IL13Rα1  (WT  in  Fig.1),  the  expression  of  the 
renilla-luciferase  construct  was  reduced  to  less 
than 50% of its activity. When the putative sites 
for  miR-155  binding  were  mutated  individually, 
both  mutants failed  to  be  regulated  by  miR-155 
(MUT1  and  MUT2  in  Fig.1).  Thus,  it  was 
concluded that miR-155 directly targets IL13Rα1 
and  that  it  binds  to  the  3’UTR  of  IL13Rα1  in 
positions 1049-1071 and 1399-1424, and that both 
sites are necessary for miRNA action. 
MiR-155  regulates  the  expression  of 
IL13Rα α α α 1 in human monocytes.  
Having  established  that  miR-155  directly 
targets  the  IL13Rα1  3’UTR,  we  aimed  to 
determine  the  effects  of  miR-155  on  the 
expression  of  this  receptor  chain  in  human 
monocytes.  It  is  known  that  miR-155  is  up 
regulated  by  several  pro-Th1  factors  during  the 
inflammatory response and that it plays a role in 
the  Th1  response  in  different  cell  types  such  as 
dendritic cells (25,26) and  macrophages (21,27). 
We  wondered  whether  miR-155  could  modulate 
the M2/alternative  activation  of  macrophages  by 
decreasing IL13Rα1 expression. This would also 
suggest a role for miR-155 in the differentiation of 
a  classically  activated  pro-Th1  macrophage.  For 
this  purpose,  we  chose  a  previously  established 
and validated monocytic cell line, THP1-155 (26). 
The THP1-155 cell line is a doubly transduced cell 
line  in  which  a  miR-155  transgene  is  under  the 
control of a Tet-On response element, a regulatory 
system described elsewhere (31). Thus, miR-155 
expression  can  be  induced  upon  addition  of 
tetracycline  or  a  derivative,  doxycycline.  This 
system  allows  miR-155  up-regulation  to  be 
isolated from other events that are also triggered 
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miR-155  over  expression  (21).  In  this  cellular 
system  we  could  determine  whether  increased 
levels of miR-155 have an effect on the expression 
of IL13Rα1 both at the protein and mRNA levels. 
Cells  were  treated  with  doxycycline  for  96  h 
allowing miR-155 over expression to occur. Cells 
were collected at 24h intervals during the course 
of  the  treatment,  for  RNA  and  protein  analysis. 
Mir-155  expression  was  checked  by  qPCR  and 
showed  a  3.5  fold  increase  (Fig.S4).  MiR-155 
effects on IL13Rα1 expression were examined at 
the  protein  level  by  Western  blotting  protein 
extracts (Fig 2A). The protein levels of IL13Rα1 
(lower band) were down-regulated in parallel with 
the  up-regulation  observed  for  miR-155. 
Densitometric  analysis  determined  that  IL13Rα1 
protein  levels  were  reduced  to  4%  when  cell 
extracts were compared at time 96 hrs and 0 hrs of 
treatment  (Fig.2A).  We  also  determined  mRNA 
levels for IL13Rα1 by RT-qPCR and found that 
the  levels  did  not  vary  significantly  during  the 
course of the treatment (Fig.2B).  
Altogether, these findings show that miR-155 
regulates  the  expression  of  IL13Rα1  in  human 
monocytes.  Up-regulation  of  MiR-155  led  to  a 
down-regulation of IL13Rα1 at the protein level 
whilst  its  mRNA  levels  remained  stable.  These 
findings  suggest  that  miR-155  is  acting  by 
blocking the translation of IL13Rα1 mRNA rather 
than promoting its degradation in THP1-155 cells. 
These  results,  together  with  the  molecular  link 
previously shown between the 3’UTR of IL13Rα1 
and miR-155, prove that IL13Rα1 is a direct target 
for miR-155 in human monocytes.  
MiR-155  reduces  the  IL13  and  IL-4-
dependent phosphorylation of STAT-6.  
Having  shown  that  miR-155  directly  targets 
IL13Rα1  in  monocytes  (Figs.  1  and  2)  we 
expected that the miR-155 dependent reduction of 
IL13Rα1 would impair the ability of macrophages 
to respond to IL-13 and IL-4. Both cytokines bind 
to  the  Type  II  IL-4  receptor,  composed  of 
heterodimers of IL13Rα1 and IL4Rα, but only IL-
4 can bind to Type I receptors (12). Upon binding 
to the Type II receptor, IL-4 and IL-13  initiate a 
signaling cascade that causes phosphorylation and 
activation of STAT6 which is then able to perform 
its  transcriptional  roles  (13)  .  An  impaired 
response to IL-13 and IL-4, cytokines that promote 
M2/alternative  activation  in  macrophages,  would 
bias the macrophages towards a more M1/classical 
activation.  Hence,  we  predicted  that  by  down-
regulating the levels of IL13Rα1 miR-155 would 
modulate  the  downstream  signaling  cascade  and 
reduce STAT6 phosphorylation.  
In order to test the effects of miR-155 levels 
on  STAT6  phosphorylation  we  used  THP1-155 
cells,  in  which  miR-155  over-expression  can  be 
induced  upon  the  addition  of  doxycycline. 
Moreover, STAT6 phosphorylation can be seen as 
an indicator of the status of the Th2 pathway (13). 
THP-1-155 cells were treated (+Doxy) or not (- 
Doxy) with doxycycline for 5 days to allow miR-
155 over-expression. Cells were then starved over 
night before stimulation with IL-13 (10ng/ml) or 
IL-4 (250U/ml). When miR-155 was up-regulated 
(+Doxy),  IL-4  and  IL-13-induced  STAT6 
phosphorylation was reduced below basal levels (-
Doxy).  In  the  case  of  IL-13  stimulation,  the 
reduction  in  phospho-STAT6  levels  was  more 
pronounced (41% remaining) than in the case of 
IL-4  (67%  phospho-STAT6  remaining).  These 
data point to a more pronounced inhibitory effect 
by miR-155 on the IL-13 pathway than on the IL-4 
one. This could be due to signaling from the Type 
I  IL4  receptor  in  the  case  of  IL-4,  as  IL-13-
dependent STAT6 phosphorylation depends solely 
on  its  binding  to  IL13Rα1  (12).  We  therefore 
aimed  to  dissect  the  role  of  miR-155  on  IL-13 
signaling  through  STAT6  phosphorylation,  as  it 
relies on the presence of the direct target of miR-
155 IL13Rα1.  
We then assayed the duration and timing of 
the effects of miR-155 on IL-13 dependent STAT6 
signaling. For this purpose, THP1-155 cells were 
treated  or  not  with  doxycycline  over  96h, 
respectively  allowing  (or  not)  miR-155  over-
expression to occur. After this, cells were starved 
over  night  before  stimulation  with  IL-13.  Cells 
were collected and lysed 30min, 1h and 2h post 
IL-13 stimulation, and protein extracts subjected 
to Western blotting in order to detect the course of 
STAT6 phosphorylation. 
In cells with basal levels of miR-155 (- Doxy), 
IL-13-induced STAT6 phosphorylation reached a 
peak after 30 min and decreased over the course of 
2h, (Fig 3B, upper panel). In cells over-expressing 
miR-155  (+  Doxy)  STAT6  phosphorylation  was 
reduced  when  compared  to  non-over-expressing 
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Fig.3A.  .  Quantification  of  P-STAT6/β-Tubulin 
(Fig  3B,  lower  panel)  showed  that  the  peak  of 
STAT6  phosphorylation  was  abrogated  when 
miR-155  was  over-expressed  (+  Doxy)  To 
determine whether this effect could reflect a direct 
targeting of STAT6 by miR-155, we analysed the 
levels of total STAT6 protein in Western blots of 
the same cell extracts. STAT6 protein levels were 
not affected by over-expression of miR-155 (Fig 
3C); therefore, miR-155 is acting at an upstream 
step of the IL-13 signaling pathway, most likely 
by targeting IL13Rα1 as shown in Figs. 1 and 2. 
Our results suggest that miR-155 is reducing the 
STAT6  dependent  alternative  activation  of 
macrophages. 
MiR-155  regulates  IL13Rα α α α1  and  STAT6 
phosphorylation in human macrophages. 
Having  shown  that  miR-155  directly  targets 
IL13Rα1  and  that  up-regulation  of  miR-155  in 
THP1-155  cells  reduces  the  expression  of 
IL13Rα1  with  diminished  downstream 
phosphorylation of STAT6, we next investigated 
in a “reverse” model whether down-regulation of 
miR-155  would  increase  IL13Rα1  levels  and 
STAT6 activation in human primary macrophages. 
Human macrophages were transfected with either 
specific  anti-miR-155  oligonucleotides  or  a 
negative  control.  Three  days  after  transfection, 
cells were treated (or not) with IL-13 and collected 
after 2 hrs. Prior to this treatment, a group of cells 
was collected in order to determine expression of 
miR-155.  Figure  S9  shows  that  miR-155  was 
effectively  knocked  down.  Cell  lysates  collected 
after 2hrs of treatment were subjected to Western 
blot detection in order to determine the levels of 
IL13Rα1  protein.  Down-regulation  of  miR-155 
resulted  in  increased  expression  of  IL13Rα1 
protein, both in IL-13 treated or unstimulated cells 
(Fig 4A), thus confirming that miR-155 regulates 
IL13Rα1 in primary macrophages. The presence 
of phospho-STAT6 was also assessed in Western 
blots  of  cell  lysates.  As  expected,  the  IL-13 
dependent  phosphorylation  of  STAT6  was 
affected by miR-155 levels (Fig.4B); when miR-
155  was  blocked  (anti-miR-155)  the 
phosphorylated and active form of STAT6 showed 
a 2.7 fold increase compared to cells transfected 
with anti-miR-control. Interestingly, the levels of 
mRNA  of  IL13Rα1  remained  constant  (Fig.4C) 
suggesting that miR-155 targeting effects are due 
to the blocking of translation of IL13Rα1 mRNA 
into protein. These data show that miR-155 down-
regulates  the  levels  of  IL13Rα1  in  human 
macrophages,  thereby  reducing  the 
phosphorylation of STAT6.  
MiR-155  regulates  the  IL-13  cascade  in 
human macrophages.  
Importantly,  IL13Rα1  is  not  only  a  key 
component  in  the  IL-13  cascade  but  is  also  a 
marker for alternative activation of macrophages 
(2), suggesting a possible role for miR-155 in the 
“M type” or “Th” profile of these cells. MiR-155 
has been shown to play an important role in the 
inflammatory profile of macrophages (21) and it is 
known that STAT6 is the main mediator in the Th2 
signaling  cascade  triggered  by  IL-13  (13).  Our 
results  show  that  miR-155  directly  targets 
IL13Rα1  (Fig.1);  that  the  levels  of  miR-155 
regulate  the  expression  of  IL13Rα1  in 
macrophages  (Figs.  2  and  4)  with  consequent 
effects on the phosphorylation of STAT6 (Figs. 3 
& 4). We next aimed to test the influence of miR-
155  levels  on  the  transcriptional  profile  of 
macrophages  stimulated  with  IL-13,  i.e.  M2  or 
alternatively activated macrophages (2).  
Human  primary  monocytes  were  transfected 
with  specific  anti-miR-155  inhibitors  or  control 
anti-miR  oligonucleotides.  Three  days  post 
transfection cells were stimulated or not with IL-
13 for 24h, lysed and RNA extracted and analyzed 
by RT-qPCR.  Based on our previous results, we 
hypothesized that reducing the levels of miR-155 
would lead to an increase in the IL-13 dependent 
expression  of  several  target  genes  in  the  IL-13 
cascade.  To  test  this,  we  determined  the 
expression of genes known to be involved in the 
STAT6  cascade  and/or  alternative  activation  of 
macrophages  (2,13).  Stimulation  with  IL-13 
increased the levels of expression of SOCS1, DC-
SIGN,  CCL18,  CD23  and  SERPINE  (Fig.  5A). 
This occurred both in cells transfected with control 
anti-miR  and  active  anti-miR-155  although,  as 
expected,  the  up-regulation  was  significantly 
greater in the cells in which miR-155 was knocked 
down  (Fig.5).  MiR-155  levels  did  not  seem  to 
affect  significantly  the  basal expression  of  these 
genes  with  the  exception  of  DC-SIGN  and 
SERPINE.  We  also  assayed  other  genes  that 
showed  no  statistical  difference,  including 
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conclude  that  microRNA  155  directly  targets 
IL13Rα1  in  human  macrophages,  that  it  has  an 
effect on the activation of STAT6 and that miR-
155 levels play a key role in the IL-13 pathway, 
contributing  to  the  expression  profile  and 




In this work we have shown that microRNA-
155  modulates  the  response  of  human 
macrophages to IL-13,  a crucial cytokine in the 
programming of Th2 responses (8), and we have 
shown that miR-155 regulates the IL-13 dependent 
expression profile of these cells. We also provide 
evidence regarding the mechanism underlying this 
role,  showing  that  miR-155  directly  targets 
IL13Rα1, a key component of the Type II  IL-4 
receptor (11). In order to study the role of miR-
155  in  the  immune  profile  of 
monocytes/macrophages  we  used  a  previously 
generated  cell  line,  THP1-155  cells  (26)  and 
primary human macrophages in which we blocked 
miR-155  expression. Thus,  our  study  provides a 
molecular mechanism by which miR-155 regulates 
the response of human macrophages to IL-13.  
From  our  bioinformatic  analysis  (miRanda, 
RNAHybrid,  PITA  algorithm)  IL13Rα1  was 
predicted as a putative target of miR-155, with two 
binding  sites  mapped  at  positions  1049  –site  1- 
and  1399  –site2-  in  the  3’UTR  of  IL13Rα1 
mRNA. To determine the role of these potential 
binding sites, we used a renilla luciferase reporter 
assay  to  show  that  miR-155  directly  targets  the 
3’UTR  of  IL13Rα1  (Fig.1).  Interestingly,  both 
binding sites contributed to the inhibitory role of 
miR-155, since when either site was mutated the 
effect  of  mir-155  was  almost  completely 
abrogated. Both miRNA-target pairs present free 
energy  values  (S1)  just  below  the  -20  Kcal/mol 
cut-off  suggested  by  Watanabe  et  al  (32),  and 
above other strong target sites for miR-155 studied 
by us (PU.1 and SMAD2, approx -26 Kcal/mol, 
(26) and manuscript under revision). Additionally, 
both  sites  are  conserved  across  several  species 
(Supplement  Figs.  S2  and  S3)  although  the 
conservation is not as wide as in the previously 
mentioned examples PU.1 and SMAD2. Thus, this 
relatively  weaker  binding  regions  could  explain 
why miR-155 needs both site 1 and site 2 intact in 
order to block expression of IL13Rα1 and points 
towards  a  possible  co-operation  between  both 
sites,  which  has  also  been  suggested  to  lead  to 
translational  repression  of  the  target  gene  rather 
than mRNA degradation (33,34).  
We next performed a series of experiments in 
a cell model, THP1-155 that allows experimental 
augmentation  of  miR-155  levels  without  use  of 
inflammatory  stimuli  (such  as  LPS)  that  could 
affect other pathways (21). It was shown that miR-
155 up-regulation led to a decrease of IL13Rα1 at 
the protein level, while its mRNA levels remained 
stable (Figs.2A and B). This suggested that miR-
155 could be blocking the translation of IL13Rα1 
mRNA in these cells.  
We next aimed to establish the role of miR-
155 in the IL-13 signaling pathway by determining 
the  activation  of  STAT6.  STAT6  is  the  main 
mediator  in  the  IL-13/IL-4  signaling  pathway, 
becoming  phosphorylated  and  active  upon 
stimulation with these cytokines (12). The over-
expression  of  Mir-155  in  THP1-155  led  to 
diminished  STAT6  phosphorylation  without 
affecting total STAT6 protein levels (Figs.3A, B 
and C). Both IL-4 and  IL-13 signaling cascades 
seemed to be affected, which can be explained by 
the fact that both cytokines share and can signal 
through the Type II IL-4 receptor, which consists 
of  dimers  of  IL4Rα  and  IL13Rα1.  Importantly, 
only IL-4 can also signal through the Type I IL-4 
receptor,  while  IL-13  requires  the  presence  of 
IL13Rα1 in order to exert its effects. The specific 
dependence  on  IL13Rα1  of  the  IL-13  pathway 
could explain the observation that IL-13 signaling 
appeared to be more affected than that induced by 
IL-4 (Fig.3A). After this experimental observation, 
we decided to focus on the effect of miR-155 on 
IL-13 signaling. 
Having investigated the effects of mir-155 in 
the first series of experiments by augmenting its 
expression, we went on to confirm our results with 
a “reverse” experimental approach in which miR-
155  was  knocked  down  by  transfection  of  anti-
miR-155  oligonucleotides  in  human  primary 
macrophages. As expected, the reduction of miR-
155  led  to  an  increase  in  IL13Rα1  protein 
(Fig.4A)  and  in  the  IL-13  dependent 
phosphorylation of STAT6 (Fig.4B). Since IL-13 
triggers a M2 or pro-Th2 phenotype (8), we next 
























































































   8 
genes  that  are  markers  of  alternative 
activation/pro-Th2  profiling  and/or  phospho-
STAT6 dependent genes (2,13). After reducing the 
levels of miR-155, IL-13 signaling was increased 
(Fig.4), so we hypothesized an increase in the IL-
13 dependent expression of several target genes in 
the  IL-13  cascade.  Amongst  the  genes  assayed 
when miR-155 was knocked down, SOCS1, DC-
SIGN,  CCL18,  CD23  and  SERPINE  showed  a 
significant increase in their IL-13 dependent gene 
expression (Fig. 5). DC-SIGN and SERPINE also 
showed a decrease in their basal expression levels 
probably due to a parallel effect of miR-155 on 
factors that control their expression, such as PU.1 
and  SMAD2,  known  to  regulate  DC-SIGN  (35) 
and  SERPINE  (36)  respectively,  and  directly 
targeted by miR-155 (26), Louafi et al. manuscript 
in  revision].  DC-SIGN  is  a  typical  marker  for 
alternatively  activated  macrophages  (2)  and  it is 
involved  in  the  binding  and  recognition  of 
pathogens  by  the  immune  system.  We  have 
previously described the inhibitory effects of miR-
155  on  DC-SIGN  expression  in  dendritic  cells 
(26). Thus, the increased expression of DC-SIGN 
when miR-155 is down-regulated (Fig. 5) suggests 
that  miR-155  is  probably  affecting  pathogen 
binding ability also in macrophages. 
Our  results  showed  that  miR-155  blockade 
leads to increased STAT6 signaling. Since STAT6 
is  a  key  transcription  factor  involved  in  the 
generation of Th2 cells it could be supposed that 
the  pro-Th2  biased  phenotype  of  miR-155 
deficient  mice  might  involve  STAT6  regulation. 
Moreover, signaling through STAT6 also involves 
SHIP-1  (12),  a  repressor  of  M2  macrophage 
differentiation, and SHIP-1 has been demonstrated 
to be a direct target of miR-155 (37). In addition to 
this, miR-155 was recently reported to be inhibited 
by IL-10 (22), an anti-inflammatory cytokine that 
also  promotes  alternative  activation  of 
macrophages (2). Together, all these data suggest 
a central role for miR-155 in the acquisition and 
modulation  of  the  M1/M2  and  Th1/Th2  profiles. 
By targeting IL13Rα1 and modulating the STAT6 
cascade, miR-155 would shift the immune profile 
towards  a  more  pro-Th1  phenotype;  thus,  the 
regulation  of  miR-155  levels  is  key  in  order  to 
exert  and  develop  an  appropriate  and  balanced 
immune response. 
This central role seems to be confirmed by the 
fact  that  miR-155  affects  several  genes  that  are 
important to the human immune balance. CCL18 
is a cytokine associated with Th2 profiling and that 
has  also  been  shown  to  be  secreted  by  Tumor 
Associated  Macrophages  (TAMs)  (38), 
macrophages that display an M2-like profile (39); 
CD23, which binds to IgE complexes promoting 
an inflammatory response and has been shown to 
play  an  important  role  in  allergy  and  antigen 
presentation,  also  being  a  typical  marker  of  M2 
macrophages;  SOCS1  a  pro-Th2  protein,  that 
inhibits  the  Janus  kinase/signal  transducer, 
blocking the signaling of proTh1 stimuli such as 
LPS  (40,41).  SOCS1  is  reportedly  affected  by 
miR-155 by direct targeting (15,23) and our data 
suggest  that  miR-155  is  also  affecting  SOCS1 
indirectly,  by  reducing  the  ability  of  IL-13  to 
stimulate SOCS1 gene expression.  
Importantly, several of the genes affected by 
miR-155,  CCL18,  CD23  and  SOCS1,  together 
with IL13, have been shown to play a key role in 
the pathogenesis of allergy and asthma (9,42,43), 
characterised  by  an  exacerbated  Th2  profile  and 
lung remodeling, features also shown by miR-155 
deficient  mice  (16).  Additionally,  miR-155 
mediated down-regulation of the IL-13 and TGF-β 
(Louafi  et  al.  manuscript  in  revision)  dependent 
regulation  of  SERPINE  underscores  the  role  of 
miR-155 in pro-fibrotic processes that could also 
explain the previously mentioned lung remodeling, 
an  important  feature  in  asthma  and  other  lung 
diseases. 
Together, all these  data  position  miR-155  at 
the  heart  of  immune  regulation  and  with  an 
important role in the pathogenesis of diseases such 
as  asthma,  with  a  pro-fibrotic  remodeling 
component.  This  is  in  line  with  our  previous 
observation  that  miR-155  can  decrease  the 
response of macrophages to TGF-β (Louafi et al. 
manuscript in revision), which indicated that this 
microRNA affects not only the immune functions 
of  these  cells,  but  also  their  role  in  repair  and 
remodeling.  The  broad  implications  of  these 
biological functions position miR-155 as a crucial 
molecule for the fine tuning of a healthy balance 
in the immune system and justify future research 
on the clinical implications that might link miR-
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FIGURE LEGENDS 
 
Figure 1. MiR-155 directly targets the 3’UTR of IL13Rα α α α1. HeLa cells were co-transfected with a 
Renilla luciferase construct harbouring an IL13Rα1 3’UTR fragment containing the predicted binding 
sites for miR-155 (Wild Type, WT) and either an empty expression vector (“-“) or a miR-155 over-
expressing vector (miR-155). MUT1 and MUT2 correspond to mutants in each one of the predicted sites, 
Site 1 and Site 2, respectively. One of three independent experiments is shown. . ns= not significant, * p≤ 
0.05. 
 
Figure 2. Over-expression of miR-155 reduces the levels of IL13Rα α α α1 protein. THP1-155 cells 
were treated with doxycycline (“miR-155”) or not (“Control”) during the course of 96h to allow miR-
155  over  expression.  Cells  were  collected  in  intervals  of  24h  and  subjected  to  protein  and  RNA 
extraction. A. Cell lysates were subjected to Western blotting for IL13Rα1 protein detection (upper panel, 
lower  band  pointed  by  arrow)  and  normalised  against  β-tubulin  (lower  panel).  B.  Total  RNA  was 
extracted and mRNA levels of IL13Rα1 were determined by RT-qPCR. Shown is one experiment out of 
three independent ones. Statistical analysis of Western blots in S5. 
 
Figure 3. Over-expression of miR-155 reduces STAT6 phosphorylation. THP1-155 cells were 
treated with doxycycline (+) or not (-) during 96h to over-express miR-155. Cells were then starved over 
night and stimulated with either IL-4 or IL-13 or not stimulated (“Control”) and lysed at the indicated 
times. A. Analysis of STAT6 phosphorylation (P-STAT6) after 30 min of treatment was performed by 
Western blotting and normalised against β-tubulin. B. THP1-155 cells were stimulated with IL-13 or not, 
and collected after 30 min, 1 hr and 2 hr and subjected to Western Blotting. Lower panel shows % of P-
STAT6  in  B  plotted  against  time  of  treatment  as  analyzed  by  densitometry  (three  independent 
experiments shown, * p ≤ 0.05). C. THP1-155 cells treated or not with Doxycycline for 96 hrs (over-
expressing or not miR-155, respectively) were subjected to analysis of total STAT6 content by Western 
blotting and normalised against β-tubulin expression. Shown is one experiment out of three independent 
ones. Statistical analysis of Western Blots in S6. 
 
Figure  4.  MiR-155  down-regulation  increases  IL13Rα α α α1  protein  expression  and  STAT6 
phosphorylation. In a “reverse” model in human macrophages, cells were transfected with blocking 
oligonucleotides  against  miR-155  (Anti-155)  or  a  negative  control  (Control).  On  day  3  of  culture 
macrophages were stimulated with IL-13 or not and collected after 30 min. A Cell lysates were subjected 
to Western blotting in order to detect IL13Rα1 normalised against β-tubulin. B Cells lysates were used to 
determine P-STAT6 levels normalising against β-tubulin. C RNA was extracted from the same collected 
cells and mRNA of IL13Rα1 was determined by RT-qPCR. One of three independent experiments is 
shown. ns= not significant. Shown is one experiment out of three independent ones. Statistical analysis of 
Western blots in S7 and S8. 
 
Figure  5.  Down-regulation  of  miR-155  increases  the  transcription  of  several  STAT6/IL-13-
dependent genes. Human macrophages were transfected with Anti-miR-155 oligonucleotides (Anti-155) 
or a negative control (Control). On day 3 of culture cells were stimulated with or without IL-13 and 
collected 24h post stimulation to analyze mRNA expression by RT-qPCR analysis. The genes assayed 
were grouped in A Genes dependent on the IL-13/STAT6 signaling: CCL18, SOCS1, CD23, SERPINE 
and DC-SIGN and B, genes not affected by IL-13 treatment: TGFB1 IL-10. One of three independent 
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Figure 5 
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